Materials and methods for enhanced bioproduction processes
By reducing the pyruvate concentration and increasing the amino acid concentration in the bioreactor during the fed-batch process, the lactate spike problem was solved, the titer and productivity of the target protein were improved, and the product quality was enhanced.
Patent Information
- Application Number
- CN202380032389.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-16
- Filing Date
- 2023-01-31
- Publication Date
- 2024-11-22
AI Technical Summary
During the fed-batch process, the lactate spike phenomenon leads to reduced glucose metabolism, reduced product expression, and lower product quality, which is difficult to effectively solve with existing technologies.
By reducing the pyruvate concentration in the feed to the bioreactor and increasing the concentration of amino acids, such as glutamic acid, valine, and leucine, over a certain period of time, the lactate spike can be mitigated, thereby improving the titer and productivity of the target protein.
It effectively reduced lactate spikes, increased the titer and productivity of the target protein, improved product quality, and reduced the number of process runs.
Smart Images

Figure CN119013392A_ABST
Abstract
Description
[0001] 1. Cross-reference to related applications
[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 352,969 filed on June 16, 2022 and U.S. Provisional Patent Application No. 63 / 305,226 filed on January 31, 2022, the disclosures of each of which are incorporated herein by reference in their entirety. 2. Summary of the invention
[0003] In one aspect, the present invention provides a method for reducing the lactate spike in a fed-batch process for producing a target protein, wherein the method includes reducing the pyruvate concentration in one or more feeds of cells containing nucleic acids encoding the protein in a bioreactor in a fed-batch process. In another aspect, the present invention provides a method for increasing the titer of a target protein produced by a cell in a fed-batch culture process, the method including reducing the pyruvate concentration in one or more feeds of cells in a bioreactor in a fed-batch process. In some embodiments, the method also includes increasing the concentration of one or more amino acids in one or more feeds. In some embodiments, one or more amino acids are selected from the group consisting of: glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of: glutamic acid, valine and leucine or a combination thereof. In some embodiments, one or more amino acids are glutamic acid, valine or a combination thereof. In some embodiments, the amino acid concentration increases by about 0% to about 100%. In some embodiments, the pyruvate concentration decreases by about 65% to about 100%. In some embodiments, the cell is a CHO cell. In specific embodiments, the target protein is a recombinant protein. In some embodiments, the target protein is an antibody, a cytokine, an antigen, an enzyme, or a coagulant. In some embodiments, the target protein is an antibody, a cytokine, or an antigen. In some embodiments, the antibody binds to glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a fungus or a parasite. In some embodiments, the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0004] In another aspect, the present invention provides a method for producing a target protein, the method comprising: (a) in a bioreactor under conditions sufficient for cells containing nucleic acids encoding the protein to produce the protein, the cells are fed-batch cultured, wherein the fed-batch culture comprises adding a certain volume of one or more feeds (e.g., one or more composite feeds), the one or more feeds having a pyruvate concentration that is 65% to 100% lower than the pyruvate concentration used for the fed-batch culture of the cells under the same conditions under which the lactate spike is observed; and (b) purifying the protein from the cells or liquid culture medium. In some embodiments, the concentration of one or more amino acids in the one or more feeds is increased by about 0% to about 100% relative to the fed-batch culture of cells under the same conditions under which the lactate spike is observed. In some embodiments, the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid, and isoleucine, or a combination thereof. In some embodiments, the one or more amino acids are selected from the group consisting of glutamic acid, valine, and leucine, or a combination thereof. In some embodiments, the one or more amino acids are glutamic acid, valine, or a combination thereof. In some embodiments, the cell is a CHO cell. In specific embodiments, the target protein is a recombinant protein. In some embodiments, the target protein is an antibody, a cytokine, an antigen, an enzyme, or a coagulant. In some embodiments, the target protein is an antibody, a cytokine, or an antigen. In some embodiments, the antibody binds to glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a fungus or a parasite. In some embodiments, the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0005] In another aspect, a method for providing a digital computer simulation of a fed-batch process for producing a target protein is provided herein, the method being implemented by one or more computing devices, and the method comprising: receiving data characterizing a fed-batch process; initializing a model of a mammalian cell line; simulating the fed-batch process using the initialized model and the received data to characterize a lactate spike; identifying at least one factor contributing to a lactate spike based on the simulation; and providing data characterizing at least one factor identified. In some embodiments, the data provided characterizes one or more of the product composition, initial conditions, and nutrient addition of the fed-batch process. In some embodiments, the model is a metabolic model. In some embodiments, the model comprises one or more machine learning models. In some embodiments, the one or more machine learning models comprise: a neural network. In some embodiments, the method further comprises: training a neural network using data extracted from a representative process that does not exhibit a lactate spike and a representative process that exhibits a lactate spike. In some embodiments, the extracted data characterizes one or more of the product composition, initial conditions, and nutrient addition of the fed-batch process. In some embodiments, providing data includes one or more of: displaying the identified at least one factor in a graphical user interface, physically permanently storing the identified at least one factor, loading the identified at least one factor into a memory, or transmitting the identified at least one factor to a remote computing system over a network. In some embodiments, the identified at least one factor indicates that it is necessary to reduce the concentration of pyruvate in one or more feeds to cells in a bioreactor in a fed-batch process to reduce the lactate spike. In some embodiments, the identified at least one factor indicates that it is necessary to increase the concentration of one or more amino acids in one or more feeds to cells in a bioreactor in a fed-batch process to reduce the lactate spike.
[0006] In another aspect, the present invention provides a method for producing a target protein as part of a fed-batch process, the method comprising: receiving data characterizing the fed-batch process; initializing a model of a mammalian cell line; simulating a fed-batch process using the initialized model and the received data to characterize a lactate spike; based on the simulation, identifying at least one factor that contributes to the lactate spike; and modifying one or more operating parameters of the fed-batch process based on the at least one factor identified. In some embodiments, the modification comprises reducing the pyruvate concentration in one or more feeds to cells in a bioreactor in the fed-batch process. In some embodiments, the modification comprises increasing one or more amino acids in one or more feeds to cells in a bioreactor in the fed-batch process.
[0007] In another aspect, a method for reducing a lactate spike during a fed-batch culture of a cell is provided herein, the method comprising feeding a cell in a bioreactor under conditions sufficient to cause a cell comprising a nucleic acid encoding a target protein to produce the protein, wherein the fed-batch culture comprises adding a volume of a first feed (e.g., a first composite feed) within 0 to 6 days after the start of the fed-batch culture of the cell, wherein the first feed has a first pyruvate concentration, and wherein the first pyruvate concentration is about 65% to about 100% lower than the pyruvate concentration used for the same volume of the first feed in a second fed-batch culture of the cell performed under the same conditions under which a lactate spike is observed. In some embodiments, the volume of the first feed is within 0 to 3 days. In some embodiments, the volume of the first feed is within 3 to 5 days. In some embodiments, the volume of the first feed is within 3 to 6 days. In some embodiments, the volume of the first feed is within 4 to 6 days. In some embodiments, the volume of the first feed is within 5 to 6 days. In some embodiments, the concentration of one or more amino acids is increased. In some embodiments, the increase in the concentration of one or more amino acids is from about 0% to about 100%. In some embodiments, one or more amino acids are selected from the group consisting of: glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of: glutamic acid, valine and leucine or a combination thereof. In some embodiments, one or more amino acids are glutamic acid, valine or a combination thereof. In some embodiments, the cell is a CHO cell. In specific embodiments, the target protein is a recombinant protein. In some embodiments, the target protein is an antibody, a cytokine, an antigen, an enzyme or a coagulant. In some embodiments, the target protein is an antibody, a cytokine or an antigen. In some embodiments, the antibody binds to glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen.In some embodiments, the pathogen is a virus, a bacterium, a fungus or a parasite. In some embodiments, the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0008] In another aspect, provided herein is a method for identifying a pyruvate concentration for one or more feeds in a fed-batch process, the method comprising: (a) feeding a cell comprising a nucleic acid encoding a protein of interest to produce the protein in a first bioreactor under conditions sufficient for the cell to produce the protein, wherein the fed-batch culture comprises adding a volume of one or more feeds (e.g., one or more composite feeds), the one or more feeds having a first pyruvate concentration; (b) feeding a cell in a second bioreactor under the same conditions as for the fed-batch culture in step (a), except that the one or more feeds have a second pyruvate concentration, wherein the second pyruvate concentration is about 65% to about 100% lower than the first pyruvate concentration (e.g., about 65% to about 75%, about 75% to about 85%, about 85% to about 95%, about 80% to about 95%, or about 85% to about 100%); (c) measuring the lactate concentration in the fed-batch culture in step (a) within about 12 hours to about 72 hours (e.g., about 12 hours, about 18 hours, about 24 hours, about 48 hours, or about 72 hours) after each feeding batch, and measuring the lactate concentration in the fed-batch culture in step (b) within about 12 hours to about 72 hours (e.g., about 12 hours, about 18 hours, about 24 hours, about 48 hours, or about 72 hours) after each feeding batch; and (d) comparing the measured lactate concentration of the fed-batch culture in step (a) with the measured lactate concentration of the fed-batch culture in step (b), wherein a decrease in the lactate concentration of the fed-batch culture in step (b) relative to the lactate concentration of the fed-batch culture in step (a) indicates that the pyruvate concentration used for one or more feeds in the fed-batch culture in step (b) is better for fed-batch culture of cells in the bioreactor. In some embodiments, the method further comprises (e) producing the protein by fed-batch culture of the cells under conditions sufficient to produce the recombinant protein in the cells comprising the nucleic acid, wherein the fed-batch culture comprises adding a certain volume of one or more feeds, and the one or more feeds have a second pyruvate concentration. In some embodiments, the cells are CHO cells. In specific embodiments, the target protein is a recombinant protein. In some embodiments, the target protein is an antibody, a cytokine, an antigen, an enzyme, or a coagulant. In some embodiments, the target protein is an antibody, a cytokine, or an antigen.In some embodiments, the antibody binds to glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin. In some embodiments, the antibody binds to an antigen of a pathogen. In some embodiments, the pathogen is a virus, a bacterium, a fungus, or a parasite. In some embodiments, the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9, or IL-17. See Section 4.1.1 for additional information and embodiments regarding target proteins.
[0009] In another aspect, the present invention provides a method for reducing lactate spikes during fed-batch culture of cells, the method comprising feeding and culturing the cells in a bioreactor under conditions sufficient to cause cells containing nucleic acids encoding a target protein to produce the protein, wherein the fed-batch culture comprises adding one or more feeds (e.g., one or more composite feeds) during the expansion of the cells, and reducing the concentration of pyruvate in one or more additional feeds (e.g., one or more additional composite feeds) before the peak cell density, wherein during the expansion of the cells, relative to the pyruvate concentration in the one or more feeds, the pyruvate concentration in the one or more additional feeds is reduced by 65% to 100%. In some embodiments, in the fed-batch culture of cells, the peak cell density is about 6 days to about 7 days, and in the fed-batch culture of cells, the reduction in the pyruvate concentration in the one or more additional feeds is about the 3rd day to the 5th day (e.g., about the 3rd day, about the 4th day, or about the 5th day). In some embodiments, before the peak cell density, the concentration of one or more amino acids in the one or more additional feeds is increased. In some embodiments, during the expansion of the cells and before the peak cell density, the concentration of one or more amino acids in one or more additional feeds is increased by 0% to 100% relative to the concentration of one or more amino acids in one or more feeds. In some embodiments, the one or more amino acids are selected from the group consisting of: glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine or a combination thereof. In some embodiments, the one or more amino acids are selected from the group consisting of: glutamic acid, valine and leucine or a combination thereof. In some embodiments, the one or more amino acids are glutamic acid, valine or a combination thereof. In some embodiments, the cells are CHO cells. 3. Description of the drawings
[0010] Figure 1 : The bioreactor used for the fed-batch process for the production of Antibody A exhibited a lactate spike, increased glucose consumption during the lactate spike, decreased glucose consumption after the lactate spike, and increased osmolarity due to base addition. No differences in viable cell density, viability, and glutamine concentration were observed.
[0011] Figure 2 : Bioreactors for fed-batch processes producing Antibody B and Antibody C exhibited a lactate spike. No differences in viable cell density were observed.
[0012] Figure 3 : Lactate production and glucose consumption per cell in a bioreactor for a fed-batch process for the production of Antibody A, Antibody B and Antibody C.
[0013] FIG. 4A to FIG. 4C : The viable cell density of a cell culture process operated under the same conditions ( Figure 4A ), titer ( Figure 4B ) and lactate ( Figure 4C ), showing significant lactate burst accumulation (solid line), modest lactate burst accumulation (dotted line), or no lactate burst accumulation (dashed line) in the absence of apparent growth or titer differences.
[0014] FIG. 5A to FIG. 5B : Schematic diagram of the digital twin (i.e., model). Figure 5A )The digital twin consists of three separate models that together describe the dynamics of the cell culture process. Figure 5B ) Various models of digital twins are mapped to physical systems, where cells (circles), extracellular metabolites (squares), and volume manipulations (arrows) correspond to their Figure 5A , the respective models in (i.e., the kinetic cell model, the extracellular reaction model, and the reactor model, respectively).
[0015] Figure 6 : Two representative processes showing "no lactate spike" (M19L059) or "lactate spike" (M19L062) were used to train the metabolic model. For both phenotypes, the updated model parameters resulted in an accurate fit of the model (solid line) to the process data (dots).
[0016] Figure 7 : Sensitivity analysis of feed medium components on lactate formation. Positive correlation (depicted by dashed line) = increasing concentration leads to increased lactate formation. Negative correlation (depicted by solid line) = increasing concentration leads to decreased lactate formation.
[0017] Figure 8 : Diagram of TCA cycle entry points of media components most likely to influence lactate formation. Components from sensitivity analysis are underlined. Dashed lines represent multiple reactions prior to the entry point.
[0018] FIG. 9A to FIG. 9B : Experimental validation results of metrics for model identification. Fig. 9A ) compared to the lactate concentration during the previous lactate spike (dash-dotted line). Conditions with lower pyruvate (thin solid line) consistently produced lower lactate concentrations. Fig. 9B ) Normalize the titer results for each condition (n≥2) to Figure 4C Mean titers of lactate spike procedures are shown in . Error bars indicate standard deviation.
[0019] FIG. 10A to FIG. 10B : The digital twin calculates the flux distribution (in micromoles / cell / day) at 120 hours (the time of the lactate spike). Fig. 10A ) Glycolytic flux during the high lactate process, where 55% of glucose is converted to lactate. Fig. 10B ) Low pyruvate glycolytic flux, where 22% of glucose is converted to lactate and most of the carbon enters the TCA cycle.
[0020] Fig.11 : Proposed mechanisms for the lactate spike and its moderation. 1) High concentrations of extracellular pyruvate activate glucose uptake. 2) High lactate concentrations inhibit PFK in an allosteric manner, thereby reducing glycolytic flux.
[0021] Fig.12 :Experimental conditions for sensitivity analysis verification. As shown in the figure, the experimental conditions refer to Fig. 9B Those described in . 4. Specific implementation methods
[0022] 4.1 Fed-batch process method
[0023] The present disclosure relates in part to methods, systems and compositions for reducing lactate accumulation during a fed-batch process for producing proteins using a genome-based metabolic model. For example, the present disclosure addresses the phenomenon of rapid lactate accumulation (referred to herein as "lactate spike") in a fed-batch process for producing a target protein. Specifically, during fed-batch production of a target protein, cells were observed to sporadically produce 2 g / L to 3 g / L lactate within 24 hours close to peak cell density, and then excess lactate was consumed in the remainder of the fed-batch process. When this phenomenon occurs, reduced glucose metabolism, reduced product expression and reduced product quality are observed. Specifically, for the lactate spike phenomenon, it was observed that: (1) glucose consumption increased during the lactate spike, followed by a decrease in glucose consumption; (2) oxygen consumption decreased; and (3) the osmotic pressure molarity of the culture increased due to base addition. The inventors unexpectedly found that low sodium pyruvate in the composite feed eliminated the lactate spike, while, for example, improving the titer of the target protein.
[0024] In specific embodiments, the methods described herein for producing a target protein in a fed-batch process are environmentally friendly because the methods can improve the titer of the protein produced and thus reduce the number of processes that need to be run to achieve the desired amount of protein.
[0025] As used herein, the terms "about" and "approximately" mean within 20%, within 15%, within 10%, within 9%, within 8%, within 7%, within 6%, within 5%, within 4%, within 3%, within 2%, within 1% or less of a given value or range.
[0026] Fed-batch processes are generally known in the art and are used to optimize protein production (see, e.g., YM Huang et al., Biotechnol Prog. 2010 September to October; 26 (5): 1400-10). As used herein, the terms "fed-batch process", "fed-batch culture" and similar terms are used to refer to a technique for culturing cells (e.g., mammalian cell lines) in a bioreactor. Typically, a fed-batch process is a biotechnological process in which one or more nutrients are fed discretely or continuously to a bioreactor during the culture of a cell (e.g., a mammalian cell line), and wherein the target protein is retained in the bioreactor until the end of the run. Fed-batch culture is typically terminated at a certain time point, and cells and / or components in the culture medium are harvested and optionally purified.
[0027] Fed-batch processes generally involve a growth phase and a production phase. Typically, the growth phase (also referred to as seed culture) is when all components for cell culture are supplied to the bioreactor at the beginning of the culture process, and then the cell population is amplified until large-scale production is ready. Therefore, cells are inoculated in a bioreactor according to the starting cells (e.g., cell lines) at an inoculation density suitable for the initial cell growth phase. Typically, protein is produced and harvested in the production phase. See the information and embodiments about purification in Section 4.1.5.
[0028] In the fed batch process, medium is supplemented at intervals during cell culture. These feeds (e.g., composite feeds) are usually used during the production phase. During production culture, feeds can be carried out at intervals of multiple feeds per day, every day or every 2 days to 3 days. In some embodiments, in the whole duration of production culture that continues for at least one week and at most two weeks or more weeks, feeds can be carried out at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times or at least 8 times. For example, in the whole duration of production culture that continues for 1 week to 2 weeks (e.g., 1 week or 2 weeks), feeds can be carried out at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times or at least 8 times. In another example, in the whole duration of production culture that continues for 2 weeks to 4 weeks (e.g., 2 weeks, 3 weeks or 4 weeks), feeds can be carried out at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times or at least 8 times. In some embodiments, supplemental feeding can be performed daily during the culture period. Alternative culture feeding schedules are also envisioned. The feed typically contains nutrients that are depleted during the cell culture period. In some embodiments, the first feed is at day 0 to day 3.
[0029] As used herein, the term "nutrient" can refer to any compound, molecule or substance used by an organism to survive, grow, produce a target protein, or otherwise add biomass. Examples of nutrients can include carbohydrate sources (e.g., monosaccharides such as glucose, galactose, maltose or fructose, or more complex sugars), amino acids, and vitamins (e.g., B vitamins (e.g., B12), vitamin A, vitamin E, riboflavin, thiamine, and biotin).
[0030] The term "amino acid" may refer to any of the twenty standard amino acids (i.e., glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, asparagine, glutamine, tyrosine, cysteine, lysine, arginine, histidine, aspartic acid, and glutamic acid), their single stereoisomers, and their racemic mixtures. In some embodiments, the term "amino acid" refers to any of the twenty standard amino acids or their stereoisomers. In some embodiments, the amino acid is a single stereoisomer (e.g., L-stereoisomer) of any of the twenty standard amino acids. The term "amino acid" may also refer to known nonstandard amino acids, for example, 4-hydroxyproline, hydroxyproline, s-sulfocysteine, phosphotyrosine, eN,N,N-trimethyllysine, 3-methylhistidine, 5-hydroxylysine, O-phosphoserine, g-carboxyglutamate, eN-acetyllysine, co-N-methylarginine, N-acetylserine, N,N,N-trimethylalanine, N-formylmethionine, g-aminobutyric acid, histamine, dopamine, thyroxine, citrulline, ornithine, b-cyanoalanine, homocysteine, azaserine, and S-adenosylmethionine.
[0031] As used herein, the term "pyruvate" includes the free form of pyruvic acid as well as acid salts, including sodium pyruvate and other acid salts. In a specific embodiment, the pyruvate is sodium pyruvate.
[0032] In one aspect, the present invention provides a method for producing a target protein, comprising: (a) in a bioreactor under conditions sufficient for cells comprising a nucleic acid encoding the protein to produce the protein, the cells are fed-batch cultured, wherein the fed-batch culture comprises adding one or more feeds (e.g., 1, 2, 3, 4 or more feeds (e.g., a composite feed)), the one or more feeds comprising pyruvate at a concentration reduced by about 65% to about 100%; and (b) purifying the protein from the cells or liquid culture medium. In some embodiments, the pyruvate concentration is reduced by at least 65%, at least 70%, at least 75%, at least 80%, or at least 85%. In some embodiments, the pyruvate concentration is reduced by at least 90%, at least 95%, or at least 98%. In some embodiments, the pyruvate concentration is reduced by about 65% to about 80%, about 70% to about 80%, about 75% to about 85%, or about 80% to about 95%. In a specific embodiment, the pyruvate concentration reduction is relative to the pyruvate concentration used in the fed-batch process that is the same except for the pyruvate concentration and in which a lactate spike is observed. In a specific embodiment, the pyruvate concentration reduction is relative to the pyruvate concentration used in the fed-batch process that is the same except for the pyruvate concentration and / or the concentration of one or more amino acids and in which a lactate spike is observed. In some embodiments, the concentration of one or more amino acids in one or more feeds (e.g., one or more composite feeds) increases by 0% to about 100%. In some embodiments, the concentration of one or more amino acids in one or more feeds increases by 0% to 20%, 20% to 40%, 40% to 60%, 60% to 80% or 80% to 100%. In some embodiments, the concentration of one or more amino acids in one or more feeds increases by about 5% to about 25%, about 25% to about 50%, about 50% to about 75% or about 75% to about 95%. In some embodiments, the concentration of multiple amino acids in one or more feeds increases by 0% to 40%. In some embodiments, the concentration of one or more amino acids in one or more supplements is increased by at least 5%, at least 10%, at least 20%, at least 30%, or at least 40%. In some embodiments, the concentration of one or more amino acids in one or more supplements is increased by at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid, and isoleucine, or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, and leucine, or a combination thereof. In some embodiments, one or more amino acids are glutamic acid, valine, or a combination thereof.
[0033] In some embodiments, the concentration of one or more amino acids is reduced by at least 5%, at least 10%, at least 15%, at least 20%, or at least 25%. In some embodiments, the concentration of one or more amino acids is reduced by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, or at least 60%. In some embodiments, the concentration of one or more amino acids is reduced by at least 65%, at least 70%, at least 75%, at least 80%, or at least 85%. In some embodiments, the concentration of pyruvate is reduced by at least 90%, at least 95%, at least 98%, at least 99%, or 100%. In some embodiments, the concentration of one or more amino acids is reduced by about 5% to about 10%, about 10% to about 25%, about 20% to about 40%, about 25% to about 50%, about 40% to 60%, or about 50% to about 65%. In some embodiments, the concentration of one or more amino acids is reduced by about 65% to about 80%, about 70% to about 80%, about 75% to about 85%, about 80% to about 95% or about 90% to about 100%. In some embodiments, the one or more amino acids reduced are asparagine. The volume of feed (e.g., composite feed) can be 0.1mL to about 1mL, about 1mL to about 20mL, about 20mL to about 50mL, about 50mL to about 100mL, about 100mL to about 500mL or about 500mL to about 1000mL. Feed (e.g., composite feed) can have a volume of about 1L to about 10L, about 10L to about 50L, about 50L to about 100L, about 100L to about 500L or about 500L to 2000L. It will be appreciated by those skilled in the art that the volume of feed (e.g., composite feed) can be in the range of 0.05% to 10% of the working volume of the bioreactor.
[0034] In one aspect, a method for reducing / mitigating a lactate spike in a fed-batch process for producing a target protein is provided herein, the method comprising reducing the pyruvate (e.g., sodium pyruvate) concentration of one or more feeds (e.g., one or more composite feeds) to cells in a bioreactor in a fed-batch process. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 10% to about 30% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 25% to about 50% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 25% to about 75% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 50% to about 75% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 65% to about 100% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 75% to about 95% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 85% to about 98% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 10%, about 15%, about 25%, about 30%, about 35%, or about 40% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed.In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 45%, about 50%, about 55%, about 60%, about 65%, or about 70% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, about 99%, or about 100% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed.
[0035] In some embodiments, in addition to reducing the concentration of pyruvate (e.g., sodium pyruvate) of one or more feeds (e.g., one or more composite feeds) of a fed-batch process for producing a target protein, one or more feeds contain one or more amino acids of increased concentration. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, aspartic acid, isoleucine, and threonine, or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, aspartic acid, isoleucine, and threonine. In some embodiments, one or more amino acids are glutamic acid, valine, and leucine. In some embodiments, one or more amino acids are glutamic acid and valine. In some embodiments, the concentration of amino acids is increased by about 0% to about 100% relative to the concentration of amino acids present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of amino acids is increased by about 0.5% to about 10% relative to the concentration of amino acids present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 0.5%, about 1%, about 2%, about 3%, about 4%, or about 5% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 6%, about 7%, about 8%, about 9%, or about 10% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 0.5% to about 100% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 5% to about 100%, about 5% to about 75%, about 5% to about 50%, or about 5% to about 25% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of amino acid is increased by about 25% to about 100%, about 25% to about 75%, or about 25% to about 50% relative to the concentration of amino acid present in one or more feeds in the same fed-batch process in which lactate spike is observed. In some embodiments, the concentration of amino acid is increased by about 0% to about 20%, about 20% to about 40%, about 40% to about 60%, or about 20% to about 60% relative to the concentration of amino acid present in one or more feeds in the same fed-batch process in which lactate spike is observed. In some embodiments, the concentration of amino acid is increased by about 0% to about 40%, about 1% to about 40%, about 60% to about 80%, or about 80% to about 100% relative to the concentration of amino acid present in one or more feeds in the same fed-batch process in which lactate spike is observed.In some embodiments, the concentration of an amino acid is increased by at least 0.05%, at least 1%, at least 5%, at least 10%, at least 20%, at least 20%, at least 25%, at least 30%, at least 35%, or at least 40% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of an amino acid is increased by at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of an amino acid is increased by at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed.
[0036] In specific embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition). In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the fifth and sixth days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the fourth and seventh days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the third and eighth days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the second and tenth days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the fourth and fifth days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the sixth and seventh days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the seventh and eighth days of culture. In some embodiments, the lactate spike is mitigated by compound feed addition between the eighth and ninth days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) between the ninth and tenth days of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) on the third day of culture. In some embodiments, the lactate spike is mitigated by compound feed addition on the fourth day of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) on the fifth day of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) on the sixth day of culture. In some embodiments, the lactate spike is mitigated by compound feed addition on the seventh day of culture. In some embodiments, the lactate spike is mitigated by feed addition (e.g., compound feed addition) on the eighth day of culture.
[0037] In some embodiments, the cell is a mammalian cell. Non-limiting examples of mammalian host cell lines suitable for the present disclosure include Chinese hamster ovary (CHO), mouse myeloma-derived NS0 and Sp2 / 0 cells, human embryonic kidney cells (HEK293) and human embryonic retina-derived PER.C6 cells. In some embodiments, the mammalian cell line is a CHO cell line. See Section 4.1.2 for additional information and embodiments about cells.
[0038] In specific embodiments, the culture medium and feed (e.g., composite feed) used in the fed-batch process are suitable for the cells used. In specific embodiments, the culture medium and feed (e.g., composite feed) used in the fed-batch process allow the cells to be used for growth and production of the target protein. See Section 4.1.4 for additional information and embodiments about culture medium and feed.
[0039] The bioreactor for fed batch has any suitable volume that allows the cultivation and propagation of biological cells capable of producing target proteins. For example, the volume of the bioreactor can be from about 10 milliliters (mL) to about 25,000L. In another example, the volume of the bioreactor can be from about 0.5 liters (L) to about 25,000L. In some embodiments, the volume of the bioreactor can be about 10mL. In some embodiments, the volume of the bioreactor can be from about 10mL to about 100mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 200mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 300mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 500mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 750mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 1000mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 2L. In some embodiments, the volume of the bioreactor can be from about 1L to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250L. In some embodiments, the volume of the bioreactor may be about 0.5 liters (L) to about 250L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50L. In some embodiments, the volume of the bioreactor may be about 1L to about 50L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25L. In some embodiments, the volume of the bioreactor may be about 1L to about 25L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 1L. In some embodiments, the volume of the bioreactor may be about 1L. In some embodiments, the volume of the bioreactor may be about 2L. In some embodiments, the volume of the bioreactor may be about 3L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 100 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250 L. In some embodiments, the volume of the bioreactor may be equal to or greater than 1,000 L. In some embodiments, the volume of the bioreactor may be from about 1,000 L to about 25,000 L.In some embodiments, the volume of the bioreactor may be about 10,000 L to about 25,000 L. In some embodiments, the volume of the bioreactor may be about 1,000 L. In some embodiments, the volume of the bioreactor may be about 2,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 15,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25,000 L. See Section 4.1.3 for additional information and embodiments regarding bioreactors.
[0040] In some embodiments, the lactate spike occurs between the fifth and sixth days of culture. In some embodiments, the lactate spike occurs between the fourth and seventh days of culture. In some embodiments, the lactate spike occurs between the third and eighth days of culture. In some embodiments, the lactate spike occurs between the second and tenth days of culture. In some embodiments, the lactate spike occurs between the fourth and fifth days of culture. In some embodiments, the lactate spike occurs between the sixth and seventh days of culture. In some embodiments, the lactate spike occurs between the seventh and eighth days of culture. In some embodiments, the lactate spike occurs between the eighth and ninth days of culture. In some embodiments, the lactate spike occurs between the ninth and tenth days of culture. In some embodiments, the lactate spike occurs on the third day of culture. In some embodiments, the lactate spike occurs on the fourth day of culture. In some embodiments, the lactate spike occurs on the fifth day of culture. In some embodiments, the lactate spike occurs on the sixth day of culture. In some embodiments, the lactate spike occurs on the seventh day of culture. In some embodiments, the lactate spike occurs on the eighth day of culture.
[0041] In some embodiments, the lactate spike is mitigated by one or more of the following: (a) reducing asparagine, pyruvate, or a combination thereof; and / or (b) increasing glutamate, isoleucine, leucine, aspartic acid, valine, threonine, or a combination thereof. In some embodiments, the lactate spike is mitigated by an increase in one or more amino acids selected from the group consisting of glutamate, valine, leucine, threonine, aspartic acid, and isoleucine, or a combination thereof. In specific embodiments, the lactate spike is mitigated by a reduction in pyruvate. In some embodiments, the lactate spike is mitigated by an increase in glutamate, valine, leucine, or a combination thereof. In some embodiments, the lactate spike is mitigated by an increase in glutamate, valine, or a combination thereof. In certain embodiments, the lactate spike is mitigated by an increase in glutamate, valine, or a combination thereof. In some embodiments, the lactate spike is mitigated by an increase in glutamate, valine, or a combination thereof. In some embodiments, the lactate spike is moderated by an increase in glutamate, valine, or a combination thereof.
[0042] As provided herein, the relaxation of lactate spikes can improve productivity and / or product quality (e.g., capillary isoelectric focusing (cIEF), purity, glycans). In some embodiments, the productivity of a bioreactor process increases by about 5%. In some embodiments, the productivity of a bioreactor process increases by about 10%. In some embodiments, the productivity of a bioreactor process increases by about 20%. In some embodiments, the productivity of a bioreactor process increases by about 30%. In some embodiments, the productivity of a bioreactor process increases by about 40%. In some embodiments, the productivity of a bioreactor process increases by about 50%. In some embodiments, the productivity of a bioreactor process increases by about 60%. In some embodiments, the productivity of a bioreactor process increases by about 70%. In some embodiments, the productivity of a bioreactor process increases by about 80%. In some embodiments, the productivity of a bioreactor process increases by about 90%. In some embodiments, the productivity of a bioreactor process increases by greater than 100%.
[0043] In some embodiments, the mass of the product increases by about 5%. In some embodiments, the mass of the product increases by about 10%. In some embodiments, the mass of the product increases by about 20%. In some embodiments, the mass of the product increases by about 30%. In some embodiments, the mass of the product increases by about 40%. In some embodiments, the mass of the product increases by about 50%. In some embodiments, the mass of the product increases by about 60%. In some embodiments, the mass of the product increases by about 70%. In some embodiments, the mass of the product increases by about 80%. In some embodiments, the mass of the product increases by about 90%. In some embodiments, the mass of the product increases by more than 100%.
[0044] In some embodiments, the method for reducing the lactate spike increases the titer of the target protein. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 5% to about 30%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 5% to about 20%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 5% to about 15%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 5% to about 10%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 10% to about 30%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 10% to about 20%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 20% to about 30%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 25% to about 75%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 50% to about 75%. In some embodiments, the method for reducing the lactate spike increases the titer of the target protein by about 75% to about 95%.
[0045] In some embodiments, the titer increase is an increase of about 10%. In some embodiments, the titer increase is an increase of about 20%. In some embodiments, the titer increase is an increase of about 30%. In some embodiments, the titer increase is an increase of about 40%. In some embodiments, the titer increase is an increase of about 50%. In some embodiments, the titer increase is an increase of about 60%. In some embodiments, the titer increase is an increase of about 70%. In some embodiments, the titer increase is an increase of about 80%. In some embodiments, the titer increase is an increase of about 90%. In some embodiments, the titer increase is an increase of about 100%. In some embodiments, the titer increase is an increase of greater than 100%.
[0046] In some embodiments, the protein yield or titer (which can be expressed in grams of protein product per liter of culture medium) from a cell culture in accordance with the present disclosure is at least 100 mg / L, at least 1 g / L, at least 1.2 g / L, at least 1.4 g / L, at least 1.6 g / L, at least 1.8 g / L, at least 2 g / L, at least 2.5 g / L, at least 3 g / L, at least 3.5 g / L, at least 4 g / L, at least 4.5 g / L, at least 5 g / L, at least 5.5 g / L, at least 6 g / L, at least 6.5 g / L, at least 7 g / L, at least 7.5 g / L, at least 8 g / L, at least 8.5 g / L, at least 9 g / L, at least 9.5 g / L, at least 10 g / L, at least 15 g / L, or at least 20 g / L.
[0047] In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 0.5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 1 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 1.5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 2 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 2.5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 3 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by 3.5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 4 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by 4.5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by 5.5 g / L. In a specific embodiment, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 6 g / L. In some embodiments, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 0.5 g / L to about 6 g / L. In some embodiments, the reduction of pyruvate (e.g., sodium pyruvate) increases the titer by about 1 g / L to about 6 g / L, about 2 g / L to about 6 g / L, about 2 g / L to about 4 g / L. In some embodiments, a reduction in pyruvate (e.g., sodium pyruvate) increases the titer by about 3 g / L to about 6 g / L, about 4 g / L to about 6 g / L, about 3 g / L to about 5 g / L, about 3 g / L to about 4 g / L, or about 4 g / L to about 5 g / L.
[0048] In some embodiments, the method for reducing the lactate spike increases the viable cell density (VCD). In some embodiments, the method for reducing the lactate spike increases the VCD by about 5% to about 30%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 5% to about 20%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 5% to about 15%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 5% to about 10%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 10% to about 30%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 10% to about 20%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 20% to about 30%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the method for reducing the lactate spike increases the VCD by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%.
[0049] In some embodiments, the method for reducing lactate spike increases cell productivity. In some embodiments, the method for reducing lactate spike increases cell productivity by about 5% to about 30%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 5% to about 20%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 5% to about 15%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 5% to about 10%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 10% to about 30%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 10% to about 20%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 20% to about 30%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%. In some embodiments, the method for reducing lactate spike increases cell productivity by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%.
[0050] In some embodiments, the method for reducing the lactate spike increases the purity (e.g., cSDS purity). In some embodiments, the method for reducing the lactate spike increases the purity (e.g., cSDS purity) by about 10% to 40%. In some embodiments, the method for reducing the lactate spike increases the purity (e.g., cSDS purity) by about 20% to 40%. In some embodiments, the method for reducing the lactate spike increases the purity (e.g., cSDS purity) by about 30% to 40%. In some embodiments, the reduction of sodium pyruvate increases the capillary sodium dodecyl sulfate gel electrophoresis (cSDS) purity.
[0051] In some embodiments, the method for reducing the lactate spike increases the flux into the tricarboxylic acid (TCA) cycle, for example, as described in the examples below. In some embodiments, the method for reducing the lactate spike balances the rates of glycolytic flux and TCA flux. In some embodiments, the method for reducing the lactate spike achieves one, two or more or all of the effects described in the examples below.
[0052] In some embodiments, the method for reducing the lactate spike reduces saccharification. In some embodiments, the method for reducing the lactate spike reduces saccharification by about 5% to about 30%. In some embodiments, the method for reducing the lactate spike reduces saccharification by about 5% to about 20%. In some embodiments, the method for reducing the lactate spike reduces saccharification by about 5% to about 10%. In some embodiments, the method for reducing the lactate spike reduces saccharification by about 10% to about 20%. In some embodiments, the method for reducing the lactate spike reduces saccharification by about 10% to about 30%. In some embodiments, the method for reducing the lactate spike reduces saccharification by about 20% to about 30%.
[0053] In some embodiments, the reduction of pyruvate (e.g., sodium pyruvate) improves saccharification and capillary isoelectric focusing (cIEF) spectra. In some embodiments, the reduction of pyruvate (e.g., sodium pyruvate) increases glycan complexity. For example, as provided herein, relative to high pyruvate (e.g., sodium pyruvate) conditions, the reduction of pyruvate (e.g., sodium pyruvate) can reduce G0F / G0F-GlcNac and increase G1F / G2F.
[0054] In one aspect, as provided herein, the reduction of the lactate spike increases the titer of the bioreactor culture. In some embodiments, the titer increase is an increase of about 5%. In some embodiments, the titer increase is an increase of about 10%. In some embodiments, the titer increase is an increase of about 20%. In some embodiments, the titer increase is an increase of about 30%. In some embodiments, the titer increase is an increase of about 40%. In some embodiments, the titer increase is an increase of about 50%. In some embodiments, the titer increase is an increase of about 60%. In some embodiments, the titer increase is an increase of about 70%. In some embodiments, the titer increase is an increase of about 80%. In some embodiments, the titer increase is an increase of about 90%. In some embodiments, the titer increase is an increase of about 100%. In some embodiments, the titer increase is an increase greater than 100%.
[0055] In some embodiments, the protein yield or titer (which can be expressed in grams of protein product per liter of culture medium) from a cell culture in accordance with the present disclosure is at least 100 mg / L, at least 1 g / L, at least 1.2 g / L, at least 1.4 g / L, at least 1.6 g / L, at least 1.8 g / L, at least 2 g / L, at least 2.5 g / L, at least 3 g / L, at least 3.5 g / L, at least 4 g / L, at least 4.5 g / L, at least 5 g / L, at least 5.5 g / L, at least 6 g / L, at least 6.5 g / L, at least 7 g / L, at least 7.5 g / L, at least 8 g / L, at least 8.5 g / L, at least 9 g / L, at least 9.5 g / L, at least 10 g / L, at least 15 g / L, or at least 20 g / L.
[0056] In one aspect, as provided herein, the reduction of lactate spike increases the productivity of bioreactor culture. In some embodiments, the productivity increase is an increase of about 5%. In some embodiments, the productivity increase is an increase of about 10%. In some embodiments, the productivity increase is an increase of about 20%. In some embodiments, the productivity increase is an increase of about 30%. In some embodiments, the productivity increase is an increase of about 40%. In some embodiments, the productivity increase is an increase of about 50%. In some embodiments, the productivity increase is an increase of about 60%. In some embodiments, the productivity increase is an increase of about 70%. In some embodiments, the productivity increase is an increase of about 80%. In some embodiments, the productivity increase is an increase of about 90%. In some embodiments, the productivity increase is an increase of about 100%. In some embodiments, the productivity increase is an increase greater than 100%.
[0057] In one aspect, as provided herein, the reduction of the lactate spike increases the rate of the bioreactor culture. In some embodiments, the rate increase is an increase of about 5%. In some embodiments, the rate increase is an increase of about 10%. In some embodiments, the rate increase is an increase of about 20%. In some embodiments, the rate increase is an increase of about 30%. In some embodiments, the rate increase is an increase of about 40%. In some embodiments, the rate increase is an increase of about 50%. In some embodiments, the rate increase is an increase of about 60%. In some embodiments, the rate increase is an increase of about 70%. In some embodiments, the rate increase is an increase of about 80%. In some embodiments, the rate increase is an increase of about 90%. In some embodiments, the rate increase is an increase of about 100%. In some embodiments, the rate increase is an increase greater than 100%.
[0058] The target protein can be any protein that a person skilled in the art expects to produce using a fed-batch process. In a specific embodiment, the target protein can be any protein (e.g., any recombinant protein) that can be recombinantly expressed. In some embodiments, the target protein is an antibody or its antigen-binding fragment. The antibody can be monospecific, bispecific, or multispecific (e.g., trispecific). In some embodiments, the target protein is an antibody. The antibody can be monoparatopic, biparatopic, or multiparatopic. The antibody can be an antibody fusion protein. The antibody or its antigen-binding fragment can be bound to any antigen (e.g., an infectious disease antigen, a cancer antigen, or an antigen associated with another disease or condition). In some embodiments, the target protein is a cytokine. In some embodiments, the target protein is an antigen. In a specific embodiment, the target protein is a secretory protein. In some embodiments, the target protein is an enzyme (e.g., human N-acetylgalactosamine-6-sulfatase (rhGALNS) or glucocerebrosidase). The enzyme can be an enzyme used in the food industry, for example, used as an emulsifier in dairy products, baked goods, brewed foods, or winemaking, or an enzyme used in sweetener production. Enzymes can be used in the pharmaceutical industry, for example, as recombinant enzymes used as biocatalysts for preparing chiral drug intermediates, or as recombinant enzyme drugs (for example, recombinant enzymes for enzyme replacement therapy). In some embodiments, the target protein is an enzyme for enzyme replacement therapy, such as a lysosomal storage disease enzyme. In some embodiments, the target protein is agalsidase β, agalsidase α, imiglucerase, taliglucerase α, velaglucerase α, arabinocerebrosidase, sebelipase α, laronidase, idosulphatase, elosulfatase α, sulfase or alglucosidase α. The target protein can be tissue plasminogen activator (tpa), interferon (for example, IFN-α, IFN-β or IFN-γ) or anti-neural agent (for example, recombinant human butyrylcholinesterase for preventing organophosphate poisoning). In some embodiments, the target protein is a membrane-bound protein. In some embodiments, the target protein is a protein expressed in a cell. See Section 4.1.1 for other information and embodiments about the target protein.
[0059] In specific embodiments, the culture medium and feed used in the fed-batch process are suitable for the cells used. In specific embodiments, the culture medium and feed used in the fed-batch process allow the cells to be used for growth and production of the target protein. See Section 4.1.4 for additional information and embodiments about culture medium and feed.
[0060] In another aspect, a method for increasing the titer of a target protein in a fed-batch process for producing a protein is provided herein, the method comprising reducing the pyruvate (e.g., sodium pyruvate) concentration of one or more feeds (e.g., one or more composite feeds) to cells in a bioreactor in a fed-batch process. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 10% to about 30% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 25% to about 50% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 25% to about 75% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 50% to about 75% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 75% to about 95% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 85% to about 98% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 10%, about 15%, about 25%, about 30%, about 35%, or about 40% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 45%, about 50%, about 55%, about 60%, about 65%, or about 70% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which a lactate spike is observed.In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, about 99%, or 100% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by at least 65%, at least 70%, at least 75%, at least 80%, or at least 85% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by at least 90%, at least 95%, or at least 98% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 65% to about 80%, about 70% to about 80%, about 75% to about 85%, about 80% to about 95%, or about 65% to about 100% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of pyruvate (e.g., sodium pyruvate) in one or more feeds is reduced by about 65% to about 70%, about 70% to about 75%, about 75% to about 80%, about 80% to about 85%, about 90% to about 95%, or about 95% to about 100% relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds in the same fed-batch process in which the lactate spike is observed.
[0061] In some embodiments, in addition to reducing the concentration of pyruvate (e.g., sodium pyruvate) of one or more feeds (e.g., one or more composite feeds) of a fed-batch process for producing a target protein, one or more feeds contain one or more amino acids of increased concentration. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid, and isoleucine, or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, isoleucine, and threonine, or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, and leucine, or a combination thereof. In some embodiments, one or more amino acids are selected from the group consisting of glutamic acid, valine, and leucine, or a combination thereof. In some embodiments, one or more amino acids are glutamic acid, valine, or a combination thereof. In some embodiments, one or more amino acids do not include threonine. In some embodiments, the concentration of the amino acid is increased by about 0% to about 100% or about 0.5% to about 10% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 0.5%, about 1%, about 2%, about 3%, about 4%, or about 5% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 6%, about 7%, about 8%, about 9%, or about 10% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 0.5% to about 100% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by about 5% to about 100%, about 5% to about 75%, about 5% to about 50%, or about 5% to about 25% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of amino acid is increased by about 25% to about 100%, about 25% to about 75%, or about 25% to about 50% relative to the concentration of amino acid present in one or more feeds in the same fed-batch process in which lactate spike is observed. In some embodiments, the concentration of amino acid is increased by about 0% to about 20%, about 20% to about 40%, about 40% to about 60%, or about 20% to about 60% relative to the concentration of amino acid present in one or more feeds in the same fed-batch process in which lactate spike is observed. In some embodiments, the concentration of amino acid is increased by about 0% to about 40%, about 1% to about 40%, about 60% to about 80%, or about 80% to about 100% relative to the concentration of amino acid present in one or more feeds in the same fed-batch process in which lactate spike is observed.In some embodiments, the concentration of the amino acid is increased by about 0% to about 40% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by at least 0.05%, at least 1%, at least 5%, at least 10%, at least 20%, at least 20%, at least 25%, at least 30%, at least 35%, or at least 40% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. In some embodiments, the concentration of the amino acid is increased by at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% relative to the concentration of the amino acid present in one or more feeds in the same fed-batch process in which the lactate spike is observed. See Section 4.1.1 for additional information and embodiments regarding target proteins.
[0062] In some embodiments, the cell is a mammalian cell. In a specific embodiment, the cell is a mammalian cell line. Non-limiting examples of mammalian host cell lines suitable for the present disclosure include Chinese hamster ovary (CHO), mouse myeloma-derived NS0 and Sp2 / 0 cells, human embryonic kidney cells (HEK293) and human embryonic retinoblast-derived PER.C6 cells. In some embodiments, the mammalian cell line is a CHO cell line. See Section 4.1.2 for additional information and embodiments about cells.
[0063] In specific embodiments, the culture medium and feed (e.g., composite feed) used in the fed-batch process are suitable for the cells used. In specific embodiments, the culture medium and feed (e.g., composite feed) used in the fed-batch process allow the cells to be used for growth and production of the target protein. See Section 4.1.4 for additional information and embodiments about culture medium and feed.
[0064] The bioreactor for fed batch has any suitable volume that allows the cultivation and propagation of biological cells capable of producing target proteins. For example, the volume of the bioreactor can be from about 10 milliliters (mL) to about 25,000L. In another example, the volume of the bioreactor can be from about 0.5 liters (L) to about 25,000L. In some embodiments, the volume of the bioreactor can be about 10mL. In some embodiments, the volume of the bioreactor can be from about 10mL to about 100mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 200mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 300mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 500mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 750mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 1000mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 2L. In some embodiments, the volume of the bioreactor can be from about 1L to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250L. In some embodiments, the volume of the bioreactor may be about 0.5 liters (L) to about 250L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50L. In some embodiments, the volume of the bioreactor may be about 1L to about 50L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25L. In some embodiments, the volume of the bioreactor may be about 1L to about 25L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 1L. In some embodiments, the volume of the bioreactor may be about 1L. In some embodiments, the volume of the bioreactor may be about 2L. In some embodiments, the volume of the bioreactor may be about 3L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 100 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250 L. In some embodiments, the volume of the bioreactor may be equal to or greater than 1,000 L. In some embodiments, the volume of the bioreactor may be from about 1,000 L to about 25,000 L.In some embodiments, the volume of the bioreactor may be about 10,000 L to about 25,000 L. In some embodiments, the volume of the bioreactor may be about 1,000 L. In some embodiments, the volume of the bioreactor may be about 2,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 15,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25,000 L. See Section 4.1.3 for additional information and embodiments regarding bioreactors.
[0065] In some embodiments, the method increases the titer of the target protein by about 5% to about 30%. In some embodiments, the method increases the titer of the target protein by about 5% to about 20%. In some embodiments, the method increases the titer of the target protein by about 5% to about 15%. In some embodiments, the method increases the titer of the target protein by about 5% to about 10%. In some embodiments, the method increases the titer of the target protein by about 10% to about 30%. In some embodiments, the method increases the titer of the target protein by about 10% to about 20%. In some embodiments, the method increases the titer of the target protein by about 20% to about 30%. In some embodiments, the method increases the titer of the target protein by about 5%, about 10%, about 15%, about 20%, about 25% or about 30%. In some embodiments, the method increases the titer of the target protein by about 25% to about 75%. In some embodiments, the method increases the titer of the target protein by about 50% to about 75%. In some embodiments, the methods increase the titer of the target protein by about 75% to about 95%.
[0066] In some embodiments, the titer increase is an increase of about 10%. In some embodiments, the titer increase is an increase of about 20%. In some embodiments, the titer increase is an increase of about 30%. In some embodiments, the titer increase is an increase of about 40%. In some embodiments, the titer increase is an increase of about 50%. In some embodiments, the titer increase is an increase of about 60%. In some embodiments, the titer increase is an increase of about 70%. In some embodiments, the titer increase is an increase of about 80%. In some embodiments, the titer increase is an increase of about 90%. In some embodiments, the titer increase is an increase of about 100%. In some embodiments, the titer increase is an increase of greater than 100%.
[0067] In some embodiments, the protein yield or titer (which can be expressed in grams of protein product per liter of culture medium) from a cell culture in accordance with the present disclosure is at least 100 mg / L, at least 1 g / L, at least 1.2 g / L, at least 1.4 g / L, at least 1.6 g / L, at least 1.8 g / L, at least 2 g / L, at least 2.5 g / L, at least 3 g / L, at least 3.5 g / L, at least 4 g / L, at least 4.5 g / L, at least 5 g / L, at least 5.5 g / L, at least 6 g / L, at least 6.5 g / L, at least 7 g / L, at least 7.5 g / L, at least 8 g / L, at least 8.5 g / L, at least 9 g / L, at least 9.5 g / L, at least 10 g / L, at least 15 g / L, or at least 20 g / L.
[0068] In some embodiments, the method increases VCD. In some embodiments, the method increases VCD by about 5% to about 30%. In some embodiments, the method increases VCD by about 5% to about 20%. In some embodiments, the method increases VCD by about 5% to about 15%. In some embodiments, the method increases VCD by about 5% to about 10%. In some embodiments, the method increases VCD by about 10% to about 30%. In some embodiments, the method increases VCD by about 10% to about 20%. In some embodiments, the method increases VCD by about 20% to about 30%. In some embodiments, the method increases VCD by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%.
[0069] In some embodiments, the method increases cell productivity. In some embodiments, the method increases cell productivity by about 5% to about 30%. In some embodiments, the method increases cell productivity by about 5% to about 20%. In some embodiments, the method increases cell productivity by about 5% to about 15%. In some embodiments, the method increases cell productivity by about 5% to about 10%. In some embodiments, the method increases cell productivity by about 10% to about 30%. In some embodiments, the method increases cell productivity by about 10% to about 20%. In some embodiments, the method increases cell productivity by about 20% to about 30%. In some embodiments, the method increases cell productivity by about 5%, about 10%, about 15%, about 20%, about 25% or about 30%. In some embodiments, the method increases cell productivity by about 5%, about 10%, about 15%, about 20%, about 25% or about 30%.
[0070] In some embodiments, the method increases purity (e.g., cSDS purity). In some embodiments, the method increases purity (e.g., cSDS purity) by about 10% to 40%. In some embodiments, the method increases purity (e.g., cSDS purity) by about 20% to 40%. In some embodiments, the method increases purity (e.g., cSDS purity) by about 30% to 40%.
[0071] In some embodiments, the method reduces saccharification. In some embodiments, the method reduces saccharification by about 5% to about 30%. In some embodiments, the method reduces saccharification by about 5% to about 20%. In some embodiments, the method reduces saccharification by about 5% to about 10%. In some embodiments, the method reduces saccharification by about 10% to about 20%. In some embodiments, the method reduces saccharification by about 10% to about 30%. In some embodiments, the method reduces saccharification by about 20% to about 30%.
[0072] In some embodiments, the method improves saccharification and capillary isoelectric focusing (cIEF) spectra. In some embodiments, the method increases glycan complexity. For example, as provided herein, relative to high pyruvate (e.g., sodium pyruvate) conditions, the method reduces G0F / G0F-GlcNac and increases G1F / G2F.
[0073] In another aspect, provided herein is a method for reducing a lactate spike during a fed-batch culture of cells, the method comprising feeding and culturing the cells in a bioreactor under conditions sufficient for cells comprising a nucleic acid encoding a target protein to produce the protein, wherein the fed-batch culture comprises adding one or more feeds (e.g., one or more composite feeds) during an expansion phase of the cells, and reducing the concentration of pyruvate in one or more additional feeds (e.g., one or more additional composite feeds) prior to peak cell density, wherein during the expansion phase of the cells, the pyruvate concentration in the one or more additional feeds is reduced by 65% to 100% relative to the pyruvate concentration in the one or more feeds. This is based at least in part on observations of when a lactate spike occurs in a fed-batch culture. As shown in Section 5, the lactate spike occurs during the expansion phase and before the cells reach a peak viable cell density (see, e.g., Figure 1 , Figure 2 and FIG. 4A to FIG. 4C). In a specific embodiment, provided herein is a method for reducing a lactate spike during a fed-batch culture of cells, the method comprising feeding a batch culture of the cells in a bioreactor under conditions sufficient for the cells comprising a nucleic acid encoding a target protein to produce the protein, wherein the fed-batch culture comprises adding one or more feeds (e.g., one or more composite feeds) during the expansion of the cells, and reducing the concentration of pyruvate in one or more additional feeds (e.g., one or more additional composite feeds) before the peak cell density, wherein during the expansion phase of the cells, the pyruvate concentration in the one or more additional feeds is reduced by 65% to 100% relative to the pyruvate concentration in the one or more feeds. In some embodiments, in the fed-batch culture of the cells, the peak cell density is about 6 days to about 7 days, and in the fed-batch culture of the cells, the reduction in the pyruvate concentration in the additional one or more feeds is about day 3 to day 5 (e.g., about day 3, about day 4, or about day 5). In some embodiments, the concentration of one or more amino acids increases before the peak cell density.
[0074] In some embodiments, during the expansion of the cell, the concentration of pyruvate in one or more additional feeds increases by about 65% to about 95% relative to the concentration of pyruvate in one or more feeds. In some embodiments, during the expansion of the cell, relative to the concentration of pyruvate, relative to the concentration of pyruvate (e.g., sodium pyruvate) present in one or more feeds, the concentration of pyruvate (e.g., sodium pyruvate) in one or more additional feeds decreases by about 75% to about 95%. In some embodiments, during the expansion of the cell, relative to the concentration of pyruvate in one or more feeds, the concentration of pyruvate (e.g., sodium pyruvate) in one or more additional feeds decreases by about 85% to about 98%. In some embodiments, during the expansion of the cell, relative to the concentration of pyruvate in one or more feeds, the concentration of pyruvate (e.g., sodium pyruvate) in one or more additional feeds decreases by about 65% or about 70% or about 65% or about 85% relative to the concentration of pyruvate in one or more feeds. In some embodiments, during expansion of the cells, the concentration of pyruvate (e.g., sodium pyruvate) in one or more additional feeds is reduced by about 75%, about 80%, about 85%, about 90%, about 95%, about 98%, about 99%, or about 100% relative to the concentration of pyruvate in one or more feeds.
[0075] In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds is increased by 0% to 100% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds is increased by about 0.5% to about 10% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds is increased by about 0.5%, about 1%, about 2%, about 3%, about 4%, or about 5% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds is increased by about 6%, about 7%, about 8%, about 9%, or about 10% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds is increased by about 0.5% to about 100% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds increases by about 5% to about 100%, about 5% to about 75%, about 5% to about 50%, or about 5% to about 25% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds increases by about 25% to about 100%, about 25% to about 75%, or about 25% to about 50% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds increases by about 0% to about 20%, about 20% to about 40%, about 40% to about 60%, or about 20% to about 60% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during the expansion of the cell, the concentration of the amino acid in one or more additional feeds increases by about 0% to about 40%, about 1% to about 40%, about 60% to about 80%, or about 80% to about 100% relative to the concentration of the amino acid in one or more feeds. In some embodiments, during expansion of the cells, the concentration of amino acids in one or more additional feeds increases by at least 0.05%, at least 1%, at least 5%, at least 10%, at least 20%, at least 20%, at least 25%, at least 30%, at least 35%, or at least 40% relative to the concentration of amino acids in one or more feeds. In some embodiments, during expansion of the cells, the concentration of amino acids in one or more additional feeds increases by at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80% relative to the concentration of amino acids in one or more feeds.In some embodiments, during expansion of the cells, the amino acid concentration in one or more additional feeds is increased by at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% relative to the amino acid concentration in one or more feeds.
[0076] In some embodiments, the cell is a mammalian cell. In a specific embodiment, the cell is a mammalian cell line. Non-limiting examples of mammalian host cell lines suitable for the present disclosure include Chinese hamster ovary (CHO), mouse myeloma-derived NS0 and Sp2 / 0 cells, human embryonic kidney cells (HEK293) and human embryonic retinoblast-derived PER.C6 cells. In some embodiments, the mammalian cell line is a CHO cell line. See Section 4.1.2 for additional information and embodiments about cells.
[0077] In specific embodiments, the culture medium and feed (e.g., composite feed) used in the fed-batch process are suitable for the cells used. In specific embodiments, the culture medium and feed (e.g., composite feed) used in the fed-batch process allow the cells to be used for growth and production of the target protein. See Section 4.1.4 for additional information and embodiments about culture medium and feed.
[0078] The bioreactor for fed batch has any suitable volume that allows the cultivation and propagation of biological cells capable of producing target proteins. For example, the volume of the bioreactor can be from about 10 milliliters (mL) to about 25,000L. In another example, the volume of the bioreactor can be from about 0.5 liters (L) to about 25,000L. In some embodiments, the volume of the bioreactor can be about 10mL. In some embodiments, the volume of the bioreactor can be from about 10mL to about 100mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 200mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 300mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 500mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 750mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 1000mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 2L. In some embodiments, the volume of the bioreactor can be from about 1L to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250L. In some embodiments, the volume of the bioreactor may be about 0.5 liters (L) to about 250L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50L. In some embodiments, the volume of the bioreactor may be about 1L to about 50L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25L. In some embodiments, the volume of the bioreactor may be about 1L to about 25L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 1L. In some embodiments, the volume of the bioreactor may be about 1L. In some embodiments, the volume of the bioreactor may be about 2L. In some embodiments, the volume of the bioreactor may be about 3L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 100 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250 L. In some embodiments, the volume of the bioreactor may be equal to or greater than 1,000 L. In some embodiments, the volume of the bioreactor may be from about 1,000 L to about 25,000 L.In some embodiments, the volume of the bioreactor may be about 10,000 L to about 25,000 L. In some embodiments, the volume of the bioreactor may be about 1,000 L. In some embodiments, the volume of the bioreactor may be about 2,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 15,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25,000 L. See Section 4.1.3 for additional information and embodiments regarding bioreactors.
[0079] In some embodiments, the method increases the titer of the target protein by about 5% to about 30%. In some embodiments, the method increases the titer of the target protein by about 5% to about 20%. In some embodiments, the method increases the titer of the target protein by about 5% to about 15%. In some embodiments, the method increases the titer of the target protein by about 5% to about 10%. In some embodiments, the method increases the titer of the target protein by about 10% to about 30%. In some embodiments, the method increases the titer of the target protein by about 10% to about 20%. In some embodiments, the method increases the titer of the target protein by about 20% to about 30%. In some embodiments, the method increases the titer of the target protein by about 5%, about 10%, about 15%, about 20%, about 25% or about 30%. In some embodiments, the method increases the titer of the target protein by about 25% to about 75%. In some embodiments, the method increases the titer of the target protein by about 50% to about 75%. In some embodiments, the methods increase the titer of the target protein by about 75% to about 95%.
[0080] In some embodiments, the titer increase is an increase of about 10%. In some embodiments, the titer increase is an increase of about 20%. In some embodiments, the titer increase is an increase of about 30%. In some embodiments, the titer increase is an increase of about 40%. In some embodiments, the titer increase is an increase of about 50%. In some embodiments, the titer increase is an increase of about 60%. In some embodiments, the titer increase is an increase of about 70%. In some embodiments, the titer increase is an increase of about 80%. In some embodiments, the titer increase is an increase of about 90%. In some embodiments, the titer increase is an increase of about 100%. In some embodiments, the titer increase is an increase of greater than 100%.
[0081] In some embodiments, the protein yield or titer (which can be expressed in grams of protein product per liter of culture medium) from a cell culture in accordance with the present disclosure is at least 100 mg / L, at least 1 g / L, at least 1.2 g / L, at least 1.4 g / L, at least 1.6 g / L, at least 1.8 g / L, at least 2 g / L, at least 2.5 g / L, at least 3 g / L, at least 3.5 g / L, at least 4 g / L, at least 4.5 g / L, at least 5 g / L, at least 5.5 g / L, at least 6 g / L, at least 6.5 g / L, at least 7 g / L, at least 7.5 g / L, at least 8 g / L, at least 8.5 g / L, at least 9 g / L, at least 9.5 g / L, at least 10 g / L, at least 15 g / L, or at least 20 g / L.
[0082] In some embodiments, the method increases VCD. In some embodiments, the method increases VCD by about 5% to about 30%. In some embodiments, the method increases VCD by about 5% to about 20%. In some embodiments, the method increases VCD by about 5% to about 15%. In some embodiments, the method increases VCD by about 5% to about 10%. In some embodiments, the method increases VCD by about 10% to about 30%. In some embodiments, the method increases VCD by about 10% to about 20%. In some embodiments, the method increases VCD by about 20% to about 30%. In some embodiments, the method increases VCD by about 5%, about 10%, about 15%, about 20%, about 25%, or about 30%.
[0083] In some embodiments, the method increases cell productivity. In some embodiments, the method increases cell productivity by about 5% to about 30%. In some embodiments, the method increases cell productivity by about 5% to about 20%. In some embodiments, the method increases cell productivity by about 5% to about 15%. In some embodiments, the method increases cell productivity by about 5% to about 10%. In some embodiments, the method increases cell productivity by about 10% to about 30%. In some embodiments, the method increases cell productivity by about 10% to about 20%. In some embodiments, the method increases cell productivity by about 20% to about 30%. In some embodiments, the method increases cell productivity by about 5%, about 10%, about 15%, about 20%, about 25% or about 30%. In some embodiments, the method increases cell productivity by about 5%, about 10%, about 15%, about 20%, about 25% or about 30%.
[0084] In some embodiments, the method increases purity (e.g., cSDS purity). In some embodiments, the method increases purity (e.g., cSDS purity) by about 10% to 40%. In some embodiments, the method increases purity (e.g., cSDS purity) by about 20% to 40%. In some embodiments, the method increases purity (e.g., cSDS purity) by about 30% to 40%.
[0085] In some embodiments, the method reduces saccharification. In some embodiments, the method reduces saccharification by about 5% to about 30%. In some embodiments, the method reduces saccharification by about 5% to about 20%. In some embodiments, the method reduces saccharification by about 5% to about 10%. In some embodiments, the method reduces saccharification by about 10% to about 20%. In some embodiments, the method reduces saccharification by about 10% to about 30%. In some embodiments, the method reduces saccharification by about 20% to about 30%.
[0086] In some embodiments, the method improves saccharification and capillary isoelectric focusing (cIEF) spectra. In some embodiments, the method increases glycan complexity. For example, as provided herein, relative to high pyruvate (e.g., sodium pyruvate) conditions, the method reduces G0F / G0F-GlcNac and increases G1F / G2F.
[0087] In another aspect, provided herein is a protein of interest produced by a method described herein (e.g., in Section 5). In a specific aspect, provided herein is a fed-batch process with reduced lactate spike as described in Section 5. The fed-batch process described herein can be used to recombinantly produce a protein of interest.
[0088] 4.1.1 Target protein
[0089] The target protein can be any protein that a person skilled in the art expects to produce using a fed-batch process. In a specific embodiment, the target protein can be any protein (e.g., any recombinant protein) that can be recombinantly expressed. In some embodiments, the target protein is an antigen binding protein. In some embodiments, the target protein is an antibody or its antigen binding fragment. In some embodiments, the target protein is an antibody. The antibody can be monospecific, bispecific, or multispecific (e.g., trispecific). The antibody can be monoparatopic, biparatopic, or multiparatopic. The antibody can be an antibody fusion protein. The antibody or its antigen binding fragment can be bound to any antigen (e.g., an infectious disease antigen, a cancer antigen, or an antigen associated with another disease or condition). In some embodiments, the target protein is a cytokine. In some embodiments, the cytokine is IL-1β, IL-2, IL-5, IL-6, IL-7, IL-9, IL-12, IL-15, IL-17, IL23, TNF-α, or an interferon (e.g., IFN-α, IFN-β, or IFN-γ). In some embodiments, the target protein is a fusion protein. In some embodiments, the target protein is an antigen. In some embodiments, the target protein is an enzyme (e.g., human N-acetylgalactosamine-6-sulfatase (rhGALNS) or glucocerebrosidase). The enzyme can be an enzyme used in the food industry, for example, used as an emulsifier in dairy products, baked goods, brewed foods, or winemaking, or an enzyme used in sweetener production. The enzyme can be used in the pharmaceutical industry, for example, as a recombinant enzyme for the preparation of a biocatalyst for a chiral drug intermediate, or as a recombinant enzyme drug (e.g., a recombinant enzyme for enzyme replacement therapy). In some embodiments, the target protein is an enzyme for enzyme replacement therapy, such as a lysosomal storage disease enzyme. In some embodiments, the target protein is agalsidase β, agalsidase α, imiglucerase, taliglucerase α, velaglucerase α, arabinocerebrosidase, sebelipase α, laronidase, idosulfatase, elosulfatase α, sulfase or alglucosidase α. The target protein can also be tissue plasminogen activator (tpa), interferon (e.g., IFN-α, IFN-β or IFN-γ), coagulation factor, erythropoietin or anti-neural agent (e.g., recombinant human butyrylcholinesterase for preventing organophosphate poisoning). In specific embodiments, the target protein is a secretory protein. In some embodiments, the target protein is a membrane-bound protein. In some embodiments, the target protein is a protein expressed intracellularly.
[0090] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein and refer to polymers of amino acids of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interspersed with non-amino acids. The term also encompasses amino acid polymers that have been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification. The definition also includes, for example, polypeptides containing one or more amino acid analogs (including but not limited to non-natural amino acids), as well as other modifications known in the art. It should be understood that because the polypeptides of the present disclosure may be based on antibodies or other members of the immunoglobulin superfamily, in certain embodiments, a "polypeptide" may appear as a single chain or as two or more related chains.
[0091] As used herein, the term "antibody" is used in the broadest sense and specifically covers, for example, monoclonal antibodies (including agonists, antagonists, neutralizing antibodies, full-length monoclonal antibodies or intact monoclonal antibodies), antibody compositions with multi-epitope specificity or mono-epitope specificity, polyclonal antibodies, monovalent antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies, as long as they exhibit the desired biological activity) (including but not limited to fusion molecules (e.g., IgG-scFv, scFv-Fc-scFv, VHH-Fc, Fc-VHH, Fc-scFv, HC-VHH, scFv-Fc-VHH, HC-scFv)), single-chain antibodies and fragments thereof (e.g., domain antibodies). Antibodies can be human, humanized, chimeric and / or affinity matured, as well as antibodies from other species such as mice, rabbits, llamas, etc. The term "antibody" is intended to include polypeptide products of B cells within the class of immunoglobulin polypeptides, which are capable of binding to a specific molecular antigen and are composed of two pairs of identical polypeptide chains, wherein each pair has one heavy chain (about 50 kDa-70 kDa) and one light chain (about 25 kDa), each amino-terminal portion of each chain including a variable region of about 100 to about 130 or more amino acids, and each carboxyl-terminal portion of each chain including a constant region. See, e.g., Antibody Engineering (Borrebaeck, ed., 2nd ed., 1995); and Kuby, Immunology (3rd edition, 1997).
[0092] Antibodies also include, but are not limited to, synthetic antibodies, nanobodies, recombinantly produced antibodies, antibodies from camelid species (e.g., llamas or alpacas) or humanized variants thereof, intrabodies, anti-idiotypic (anti-Id) antibodies, and functional fragments (e.g., antigen-binding fragments) of any of the above, which refers to a portion of an antibody heavy chain or light chain polypeptide that retains some or all of the binding activity of the antibody from which the fragment is derived. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fv (scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, diabodies, triabodies, tetrabodies, and minibodies. Specifically, antibodies provided herein include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, e.g., antigen-binding domains or molecules containing an antigen-binding site that binds to an antigen (e.g., one or more complementary determining regions (CDRs) of an antibody). Such antibody fragments may be found, for example, in Harlow and Lane, Antibodies:ALaboratoryManual (1989); Mol. Biology and Biotechnology: AComprehensive Desk Reference (Myers, ed., 1995); Huston et al., 1993, Cell Biophysics, Vol. 22: pp. 189-224; Plückthun and Skerra, 1989, Meth. Enzymol., Vol. 178: pp. 497-515; and Day, Advanced Immunochemistry (2nd edition, 1990). The antibodies provided herein can be any class (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) of immunoglobulin molecules. The antibodies can be agonistic antibodies or antagonistic antibodies. The antibodies may be neither agonistic nor antagonistic.
[0093] In some embodiments, the antibodies may have modifications, wherein the modifications include cross-linkers, glycosylation, conjugated drugs, or thiol bonds engineered through thiol.
[0094] As used herein, the term "antigen" has its ordinary meaning in the art. "Antigen" includes structures to which antigen binding proteins (e.g., antibodies) can bind. Antigens can be polypeptides, carbohydrates, nucleic acids, lipids, haptens, or other naturally occurring or synthetic compounds. In some embodiments, the antigen is a polypeptide. In certain embodiments, the antigen is associated with a cell, for example, present on or in a cell. In some embodiments, the antigen is associated with a cancer cell, for example, present on or in a cancer cell. In certain embodiments, the antigen is associated with a pathogen (such as a virus, bacteria, fungus, or parasite).
[0095] As used herein, the term "antigen binding protein" refers to a protein that binds to an antigen. Antibodies are examples of antigen binding proteins. Antigen binding proteins include, but are not limited to, for example, single-chain antibodies, nanobodies, multidomain antibodies, scFv, Fab, and diabodies.
[0096] The term "binds" or "binding" refers to interactions between molecules, including, for example, the formation of a complex. The interaction can be, for example, a non-covalent interaction, including hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. A complex can also include a combination of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The strength of the total non-covalent interactions between a single antigen binding site (such as an antigen binding site on an antibody) and a single epitope of a target molecule (such as an antigen) is the affinity of the antibody for that epitope. The dissociation rate (k) of a binding molecule (e.g., an antibody) from a monovalent antigen is the affinity of the antibody for that epitope. off ) and the association rate (k on ) ratio (k off / k on ) is the dissociation constant K D , which is inversely proportional to affinity. K D The lower the value, the higher the affinity of the antibody. D The value varies with different complexes of antibody and antigen and depends on the k on and k off Both. The dissociation constant K of the antibodies provided herein D Can use any method provided herein or any other method well-known to those skilled in the art to determine.The affinity at a binding site does not always reflect the true intensity of the interaction between antibody and antigen.When a composite antigen (such as a multivalent antigen) containing multiple repeated antigenic determinants contacts an antibody containing multiple binding sites, the interaction between antibody and antigen at one site will increase the probability of reacting at a second site.The intensity of this multiple interaction between multivalent antibody and antigen is called avidity.
[0097] Antigen binding proteins that bind to or specifically bind to an antigen can be detected, for example, by immunoassays (e.g., ELISA, radioimmunoassay, and electrochemiluminescent immunoassay), Surface plasmon resonance (e.g. ) or other techniques known to those skilled in the art. In some embodiments, a binding protein specifically binds to an antigen when it binds to the antigen with a higher affinity than to any cross-reactive antigen, as determined using experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, a specific or selective reaction will be at least twice the background signal or noise, and can be more than 10 times the background. See, for example, Fundamental Immunology , pp. 332-336 (Paul ed., 2nd ed., 1989) for a discussion of binding specificity. In certain embodiments, the extent of binding of an antigen binding protein to a "non-target" protein is less than about 10% of the binding of the antigen binding protein to its specific target antigen, e.g., as determined by fluorescence activated cell sorting (FACS) analysis or RIA. An antigen binding protein that binds to an antigen includes a binding molecule or antigen binding domain that is capable of binding to the antigen with sufficient affinity such that the antigen binding protein can be used, for example, as a therapeutic and / or diagnostic agent that targets the antigen. In certain embodiments, the antigen binding protein binds to the antigen with a dissociation constant (K) of less than or equal to 1 μM, 800 nM, 600 nM, 550 nM, 500 nM, 300 nM, 250 nM, 100 nM, 50 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. D ). In certain embodiments, the antigen binding protein binds to an antigenic epitope that is conserved among antigens from different species.
[0098] In certain embodiments, the antigen binding protein may comprise a "chimeric" sequence in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to a corresponding sequence in an antibody derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567; and Morrison et al., 1984, Proc. Natl. Acad. Sci. USA, Vol. 81: pp. 6851-6855). Chimeric sequences may include humanized sequences.
[0099] In certain embodiments, antigen-binding proteins can include a portion of a "humanized" form of a non-human (e.g., camelid, mouse, non-human primate) antibody, which includes sequences from human immunoglobulins (e.g., receptor antibodies), wherein natural complementary determining region (CDR) residues are replaced with residues from non-human species such as camelids, mice, rats, rabbits or non-human primates (e.g., donor antibodies) with desired specificity, affinity and ability corresponding to CDRs. In some cases, one or more FR region residues of a human immunoglobulin sequence are replaced with corresponding non-human residues. In addition, humanized antibodies may include residues that are not present in receptor antibodies or donor antibodies. These modifications are made to further improve antibody performance. Humanized antibody heavy or light chains may include substantially all at least one or more variable regions, wherein all or substantially all CDRs correspond to those of non-human immunoglobulins, and all or substantially all FRs are those of human immunoglobulin sequences. In certain embodiments, the humanized antibody will comprise at least a portion of an immunoglobulin constant region (Fc), typically at least a portion of a constant region of a human immunoglobulin. For more details, see Jones et al., Nature, Vol. 321: pp. 522-525, 1986; Riechmann et al., Nature, Vol. 332: pp. 323-329, 1988; Presta, Curr. Op. Struct. Biol., 2: 593-96 (1992); Carter et al., Proc. Natl. Acad. Sci. USA, Vol. 89: pp. 4285-4289, 1992; U.S. Pat. Nos. 6,800,738, 6,719,971, 6,639,055, 6,407,213, and 6,054,297.
[0100] In certain embodiments, the antigen binding protein may comprise a portion of a "fully human antibody" or "human antibody," wherein these terms are used interchangeably herein and refer to antibodies comprising human variable regions and, for example, human constant regions. The antigen binding protein may comprise an antibody sequence. In specific embodiments, these terms refer to antibodies comprising variable and constant regions of human origin. In certain embodiments, a "fully human" antibody may also encompass an antibody that binds to a polypeptide and is encoded by a nucleic acid sequence that is a naturally occurring somatic variant of a human germline immunoglobulin nucleic acid sequence. The term "fully human antibody" includes antibodies having variable and constant regions corresponding to human germline immunoglobulin sequences as described by Kabat et al. (see Kabat et al., 1991, Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). A "human antibody" refers to an antibody having an amino acid sequence corresponding to the amino acid sequence of an antibody produced by a human and / or that has been prepared using any technique for preparing human antibodies. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., Vol. 227: p. 381, 1991; Marks et al., J. Mol. Biol., Vol. 222: p. 581, 1991) and yeast display libraries (Chao et al., Nature Protocols, Vol. 1: pp. 755-768, 2006). Methods that can also be used to prepare human monoclonal antibodies are described in Cole et al., Monoclonal Antibodies and Cancer Therapy , p. 77, 1985; Boerner et al., J. Immunol., Vol. 147 No. 1: pp. 86-95, 1991; and van Dijk and van de Winkel, Curr. Opin. Pharmacol., Vol. 5: pp. 368-374, 2001. Human antibodies can be prepared by administering an antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge but whose endogenous loci have been disabled, such as mice (see, e.g., Jakobovits, Curr. Opin. Biotechnol., Vol. 6 No. 5: pp. 561-566, 1995; Brüggemann and Taussing, Curr. Opin. Biotechnol., Vol. 8 No. 4: pp. 455-458, 1997; and about the XENOMOUSE TM Nos. 6,075,181 and 6,150,584 for human antibodies generated via human B cell hybridoma technology). See also, e.g., Li et al., Proc. Natl. Acad. Sci. USA, Vol. 103: 3557-3562, 2006 for human antibodies generated via human B cell hybridoma technology.
[0101] In certain embodiments, the antigen binding protein may comprise a portion of a "recombinant human antibody", wherein the phrase includes human antibodies prepared, expressed, generated or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant combinatorial human antibody library, antibodies isolated from transgenic and / or transchromosomal animals (e.g., mice or cows) of human immunoglobulin genes (see, e.g., Taylor, LD et al., Nucl. Acids Res., Vol. 20: pp. 6287-6295, 1992) or antibodies prepared, expressed, generated or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies may have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, EA et al., 1991, Sequences of Proteins of Immunological Interest , Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when transgenic animals for human Ig sequences are used, in vivo somatic mutagenesis), and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire in vivo.
[0102] In certain embodiments, the antigen binding protein may comprise a portion of a "monoclonal antibody", wherein the term as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, e.g., except for naturally occurring mutations that may be present in small amounts or well-known post-translational modifications such as amino acid isomerization or deamidation, methionine oxidation, or asparagine or glutamine deamidation, the individual antibodies that make up the population are identical, and each monoclonal antibody will generally recognize a single epitope on the antigen. In specific embodiments, as used herein, a "monoclonal antibody" is an antibody produced by a single hybridoma or other cell. The term "monoclonal" is not limited to any particular method for preparing an antibody. For example, monoclonal antibodies useful in the present disclosure may be prepared by the hybridoma method first described by Kohler et al., Nature, Vol. 256: p. 495, 1975, or may be prepared using recombinant DNA methods in bacteria or eukaryotic or plant cells (see, e.g., U.S. Pat. No. 4,816,567). "Monoclonal antibodies" can also be isolated from phage antibody libraries using techniques described, for example, in Clackson et al., Nature, Vol. 352: 624-628, 1991 and Marks et al., J. Mol. Biol., Vol. 222: 581-597, 1991. Other methods for preparing clonal cell lines and monoclonal antibodies expressed thereby are well known in the art. See, for example, Short Protocols in Molecular Biology (Ausubel et al., eds., 5th ed., 2002).
[0103] A typical 4-chain antibody unit is a heterotetrameric glycoprotein consisting of two identical light (L) chains and two identical heavy (H) chains. In the case of IgG, the 4-chain unit is usually about 150,000 daltons. Each L chain is connected to the H chain by a covalent disulfide bond, and the two H chains are connected to each other by one or more disulfide bonds according to the H chain isotype. Each H and L chain also has regularly spaced intrachain disulfide bonds. Each H chain has a variable domain (VH) at the N-terminus, followed by three constant domains (CH) of each of the α chain and the γ chain and four CH domains of the μ and ε isotypes. Each L chain has a variable domain (VL) at the N-terminus, followed by a constant domain (CL) at its other end. VL is aligned with VH, and CL is aligned with the first constant domain (CH1) of the heavy chain. It is believed that specific amino acid residues form an interface between the light chain and the heavy chain variable domains. The pairing of VH and VL together forms a single antigen binding site. For the structure and properties of antibodies of different classes, see, for example, Basic andClinical Immunology , p. 71 (Stites et al., eds., 8th ed., 1994); and Immunobiology (Janeway et al. eds., 5th ed., 2001).
[0104] As used herein, the terms "Fab" and "Fab region" have their common meanings in the art. Generally, the term "Fab" or "Fab region" refers to the region of an antibody that binds to an antigen. Conventional IgG generally comprises two Fab regions, each Fab region residing on one of the two arms of the Y-shaped IgG structure. Each Fab region is generally composed of a variable region and a constant region of each of the heavy chain and the light chain. More specifically, the variable region and constant region of the heavy chain in the Fab region are VH and CH1 regions, and the variable region and constant region of the light chain in the Fab region are VL and CL regions. VH, CH1, VL and CL in the Fab region can be arranged in various ways to confer antigen binding ability according to the present disclosure. For example, VH and CH1 regions can be on one polypeptide, and VL and CL regions can be on separate polypeptides, similar to the Fab region of conventional IgG. Alternatively, VH, CH1, VL and CL regions can all be on the same polypeptide and oriented in different orders, as described in more detail in the following section.
[0105] As used herein, the terms "variable region" and "variable domain" have their common meanings in the art in the context of antibodies. Generally, the terms "variable region", "variable domain", "V region" or "V domain" refer to a part of the light chain or heavy chain of an antibody, which is usually located at the amino terminal of the light chain or heavy chain, and has a length of about 120 to 130 amino acids in the heavy chain and a length of about 100 to 110 amino acids in the light chain, and is used for the binding and specificity of each specific antibody to its specific antigen. The variable region of the heavy chain may be referred to as "VH". The variable region of the light chain may be referred to as "VL". The term "variable" refers to the fact that some fragments of the variable region are widely different in sequence between antibodies. The V region mediates antigen binding and limits the specificity of a specific antibody to its specific antigen. However, variability is not evenly distributed over the 110 amino acid spans of the variable region. In contrast, the V region consists of less variable (e.g., relatively invariant) stretches of about 15-30 amino acids called framework regions (FRs), separated by shorter regions of greater variability (e.g., extreme variability) called "hypervariable regions," each of which is about 9-12 amino acids long. The heavy and light chain variable regions each contain four FRs, largely adopting a β-sheet configuration, connected by three hypervariable regions, which form loops connecting and in some cases forming part of the β-pleated structure. The hypervariable regions in each chain are held together in close proximity by the FRs and with the hypervariable regions from the other chain, contributing to the formation of the antigen binding site of antibodies (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest(5th edition, 1991)). The constant region is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions, such as the participation of the antibody in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The variable region between different antibodies varies widely in sequence. In a specific embodiment, the variable region is a human variable region.
[0106] The term "variable region residue numbering according to Kabat" or "amino acid position numbering as in Kabat" and variations thereof refer to the numbering system for heavy chain variable regions or light chain variable regions used for antibody compilation in Kabat et al. (supra). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to the shortening or insertion of the FR or CDR of the variable domain. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 (residue 52a according to Kabat) and three inserted residues after residue 82 (e.g., residues 82a, 82b, and 82c, etc. according to Kabat). By comparing the homologous region of the antibody sequence with the "standard" Kabat numbering sequence, the Kabat residue numbering of a given antibody can be determined. When referring to the residues in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain), the Kabat numbering system (e.g., Kabat et al., supra) is generally used. When referring to residues in the constant region of an immunoglobulin heavy chain, the "EU numbering system" or "EU index" (e.g., the EU index as reported by Kabat et al., supra) is generally used. The "EU index as in Kabat" refers to the residue numbering of the human IgG1 EU antibody. Other numbering systems have been described by, for example, AbM, Chothia, Contact, IMGT, and AHon.
[0107] As used herein, the term "heavy chain" has its ordinary meaning in the art in the context of antibodies. Generally, when used with reference to antibodies, the term "heavy chain" refers to a polypeptide chain of about 50 kDa to 70 kDa, wherein the amino terminal portion includes a variable region of about 120 to 130 or more amino acids, and the carboxyl terminal portion includes a constant region. Based on the amino acid sequence of the heavy chain constant region, the constant region can be one of five different types (e.g., isotypes), referred to as α (α), δ (δ), ε (ε), γ (γ) and μ (μ). Different heavy chains are of different sizes: α, δ and γ contain about 450 amino acids, while μ and ε contain about 550 amino acids. When combined with light chains, these different types of heavy chains produce antibodies of five well-known categories (e.g., isotypes), i.e., IgA, IgD, IgE, IgG and IgM, including four subclasses of IgG, i.e., IgG1, IgG2, IgG3 and IgG4. The sequences of heavy chains from various species are known in the art (see, e.g., theinternational ImMunoGeneTics information imgt.org).
[0108] As used herein, the term "light chain" has its ordinary meaning in the art in the context of antibodies. Generally, when used with reference to an antibody, the term "light chain" refers to a polypeptide chain of about 25 kDa, wherein the amino terminal portion includes a variable region of about 100 to about 110 or more amino acids, and the carboxyl terminal portion includes a constant region. The approximate length of the light chain is 211 to 217 amino acids. Based on the amino acid sequence of the constant domain, there are two different types, called kappa (κ) or lambda (λ). The sequences of light chains from various species are known in the art (see, e.g., the internationalImMunoGeneTics information imgt.org). As used herein, the term "constant region" or "constant domain" in the context of antibodies has its ordinary meaning in the art. Typically, the term "constant region" or "constant domain" refers to the carboxyl terminal portion of the light chain and the heavy chain, which is not directly involved in the binding of the antibody to the antigen, but exhibits various effector functions, such as interactions with Fc receptors. Typically, the term refers to the portion of the immunoglobulin molecule that has a more conservative amino acid sequence relative to the rest of the immunoglobulin (the variable region containing the antigen binding site). The constant region may include the CH1, CH2 and CH3 regions of the heavy chain and the CL region of the light chain.
[0109] As used herein, the term "framework" or "FR" in the context of antibodies has its ordinary meaning in the art. Generally, the term "framework" or "FR" refers to those variable region residues that flank the CDRs. FR residues are present in, for example, chimeric, humanized, human domain antibodies, diabodies, linear antibodies, and bispecific antibodies. FR residues are those variable domain residues other than hypervariable region residues or CDR residues.
[0110] As used herein, the term "Fc region" of an antibody has its common meaning in the art. Typically, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain, including, for example, a native sequence Fc region, a recombinant Fc region, and a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary, the human IgG heavy chain Fc region is generally defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminal. The C-terminal lysine in the Fc region (residue 447 according to the EU numbering system) can be removed, for example, during the production or purification of an antibody or by the recombinant engineering of a nucleic acid encoding an antibody heavy chain. Therefore, the composition of a complete antibody can include an antibody population having all K447 residues removed, an antibody population having no K447 residue removed, and an antibody population having an antibody mixture containing and not containing the K447 residue. A "functional Fc region" has an "effector function" in a native sequence Fc region. Exemplary "effector functions" include C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors), etc. Such effector functions generally require an Fc region in combination with a binding region or binding domain (e.g., an antibody variable region or domain), and can be assessed using various assays known to those skilled in the art. A "variant Fc region" includes an amino acid sequence that differs from the amino acid sequence of a native sequence Fc region due to at least one amino acid modification (e.g., substitution, addition, or deletion). In certain embodiments, the variant Fc region has at least one amino acid substitution compared to the native sequence Fc region or the Fc region of a parent polypeptide, for example, about one to about ten amino acid substitutions in the native sequence Fc region or the Fc region of a parent polypeptide, or about one to about five amino acid substitutions. The variant Fc region herein may have at least about 80% homology with the Fc region of a native sequence Fc region and / or a parent polypeptide, or at least about 90% homology therewith, for example, at least about 95% homology therewith.
[0111] In certain embodiments, homology is determined by sequence similarity. Modern protein sequence databases are very exhaustive. Widely used similarity search programs such as BLAST (Altschul et al. (1997); Units 3.3 and 3.4), PSI-BLAST (Altschul et al., 1997), SSEARCH (Smith and Waterman (1981); Pearson (1991), Unit 3.10), FASTA (Pearson and Lipman (1988) Unit 3.9), and HMMER3 (Johnson et al., 2010) programs can perform accurate statistical estimates to ensure that protein sequences that share significant similarity also have similar structures.
[0112] In the context of antibodies or other antibody binding proteins, the term "specificity" refers to the selective recognition of a particular epitope of an antigen by an antigen binding protein. For example, natural antibodies are monospecific. As used herein, the term "multispecific" means that an antigen binding protein has two or more antigen binding sites, at least two of which bind to different antigens. As used herein, "bispecific" means that an antigen binding protein has two different antigen binding specificities. As used herein, the term "monospecific" antibody means an antigen binding protein with one or more binding sites, each binding site binding to the same antigen.
[0113] Various commercially available antibodies are provided in Table 1 below and are suitable for production in the fed-batch process described herein as complete antibodies, as antibody fragments or as part of multispecific antibodies (e.g., fusion proteins). In addition, antibodies that bind to the same target provided in Table 1 are suitable for production in the fed-batch process described herein.
[0114] Table 1: Exemplary commercially available antibodies
[0115]
[0116]
[0117]
[0118]
[0119]
[0120]
[0121]
[0122] The antibodies that bind to the antigens of the organisms provided in Table 2 are suitable for production in the fed-batch process described herein. In addition, the antigens of the organisms provided in Table 2 are used for production in the fed-batch process described herein. In some embodiments, the target antigen produced in the fed-batch process described herein is an antigen identified in Table 3.
[0123] Table 2
[0124]
[0125]
[0126]
[0127] Table 3
[0128]
[0129] The target protein can be used in vitro, in vitro or in vivo. For example, the target protein can have therapeutic or diagnostic uses. In another example, the target protein (e.g., antigen) can be used as an immunogen. In another example, the commercial antibodies described in Table 1 can be used for the indications shown in Table 1 or other approved indications. In another example, the target protein can be used in the food industry, for example, as an emulsifier in dairy products, baked goods, brewed foods or wine manufacturing, or an enzyme used in the production of sweeteners. In another example, the target protein can be used in the pharmaceutical industry, for example, as a recombinant enzyme used as a biocatalyst for preparing chiral drug intermediates, or as a recombinant enzyme drug (e.g., a recombinant enzyme for enzyme replacement therapy). In another example, the target protein can be used as a coagulant.
[0130] 4.1.2 Cells
[0131] The cells used in the fed-batch process can belong to any cell type, such as any animal cell type (e.g., non-human mammalian cells or human cells). In some embodiments, the cell is a mammalian cell. In a specific embodiment, the cell is a mammalian cell line. Non-limiting examples of mammalian cell lines suitable for the present disclosure include Chinese hamster ovary (CHO), mouse myeloma-derived NS0 and Sp2 / 0 cells, human embryonic kidney cells (HEK293) and human embryonic retina-derived PER.C6 cells. In some embodiments, the mammalian cell line is a CHO cell line, such as used in Section 5. In some embodiments, Chinese hamster ovary (CHO) cells are -DHFR (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)). Other examples of mammalian cell lines include SV40 transformed monkey kidney CV1 cell line (COS-7, ATCC CRL1651); baby hamster kidney cells (BHK, ATCC CCL 10); mouse Sertoli cells (TM4, Mather, Biol. Reprod., Vol. 23: pp. 243-251, 1980;); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TR1 cells (Mather et al., Annals NY Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and a human hepatoma line (HepG2).
[0132] Cells can be engineered to express a target protein using techniques known to those skilled in the art. In some embodiments, cells are recombinantly engineered to express a target protein. In some embodiments, cells are recombinantly engineered to express two or more target proteins (e.g., 2, 3, 4, or 5 target proteins). Conventional techniques of molecular biology, microbiology, and immunology within the skill range of those skilled in the art can be used. Such techniques are fully explained in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Ed., Cold Spring Harbor Laboratory, New York (2001); Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999); Glover, ed., DNA Cloning, Volumes I and II (1985); Freshney, ed., Animal Cell Culture: Immobilized Cells and Enzymes (IRL Press, 1986); Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Scopes, Protein Purification: Principles and Practice (Springer Verlag, NY, 2d ed. 1987); Therapeutic Monoclonal Antibodies: From Bench to Clinic (An editor, 2009); Monoclonal Antibodies: Methods and Protocols (Albitar ed., 2010); and Antibody Engineering, Vol. 1 and Vol. 2 (Kontermann and Dübel ed., 2nd ed., 2010). In some embodiments, cells are transfected or transformed (e.g., stably transformed) with nucleic acid molecules encoding a protein of interest. Cells transfected or transformed with nucleic acid molecules include progeny or potential progeny of such cells. Progeny of such cells may differ from the parental cells transfected or transformed with nucleic acid molecules due to mutations or environmental influences that may occur in the progeny or due to integration of the nucleic acid sequence into the cell genome.
[0133] 4.1.3 Bioreactor
[0134] A bioreactor can be any culture vessel that is manufactured or engineered to manipulate or control environmental conditions. Such culture vessels are well known in the art. For example, the bioreactor can be a stainless steel stirred tank bioreactor (STR), an airlift reactor, a disposable bioreactor, or a combination thereof (e.g., a disposable bioreactor combined with a STR).
[0135] Bioreactor processes and systems have been developed for, for example, optimizing gas exchange, supplying sufficient oxygen to maintain cell growth and productivity, and removing CO. Maintaining the efficiency of gas exchange is an important criterion for ensuring successful scale-up of cell culture and protein production. Such systems are well known to those skilled in the art.
[0136] The bioreactor used for the fed-batch process described herein has any suitable volume that allows the cultivation and propagation of biological cells capable of producing target proteins. For example, the volume of the bioreactor can be from about 10 milliliters (mL) to about 25,000L. In another example, the volume of the bioreactor can be from about 0.5 liters (L) to about 25,000L. In some embodiments, the volume of the bioreactor can be about 10mL. In some embodiments, the volume of the bioreactor can be from about 10mL to about 100mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 200mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 300mL. In some embodiments, the volume of the bioreactor can be from about 100mL to about 500mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 750mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 1000mL. In some embodiments, the volume of the bioreactor can be from about 500mL to about 2L. In some embodiments, the volume of the bioreactor can be from about 1L to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250L. In some embodiments, the volume of the bioreactor may be about 0.5 liters (L) to about 250L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50L. In some embodiments, the volume of the bioreactor may be about 1L to about 50L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25L. In some embodiments, the volume of the bioreactor may be about 1L to about 25L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 1L. In some embodiments, the volume of the bioreactor may be about 1L. In some embodiments, the volume of the bioreactor may be about 2L. In some embodiments, the volume of the bioreactor may be about 3L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 100 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250 L. In some embodiments, the volume of the bioreactor may be equal to or greater than 1,000 L. In some embodiments, the volume of the bioreactor may be from about 1,000 L to about 25,000 L.In some embodiments, the volume of the bioreactor may be about 10,000 L to about 25,000 L. In some embodiments, the volume of the bioreactor may be about 1,000 L. In some embodiments, the volume of the bioreactor may be about 2,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 15,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25,000 L.
[0137] 4.1.4 Culture medium
[0138] In a specific embodiment, the culture medium used in the fed-batch process described herein is suitable for the cells used. In a specific embodiment, the culture medium used in the fed-batch process allows cells to be used for growth and production of target proteins. In a specific embodiment, the feed (e.g., composite feed) of the fed-batch process comprises a culture medium that allows cells to be used for growth and / or production of target proteins. In a specific embodiment, one or more feeds are composite feeds. For example, commercially available culture media such as Ham's F10 (Sigma), minimal essential medium ((MEM), Sigma), RPMI-1640 (Sigma) and Dulbecco's modified Eagle's medium ((DMEM), Sigma) can be used for fed-batch processes. The culture medium can be supplemented with hormones and / or other growth factors (e.g., insulin, transferrin or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium and phosphate), buffers (e.g., HEPES or NaHCO3), nucleotides (e.g., adenosine and thymidine), antibiotics (such as GENTAMYCIN TM Drugs), trace elements (defined as inorganic compounds typically present at final concentrations in the micromolar range), and glucose or an energy source in an equivalent form (e.g., another sugar). The culture medium can be a serum-free medium. Buffers are generally known in the art. The present disclosure is not limited to any particular buffer, and one of ordinary skill in the art can select an appropriate buffer or buffer system for a particular cell line producing a particular protein. Culture conditions, such as temperature, pH, etc. are those previously used with the cells selected for expression and are apparent to the ordinary skilled person. Typically, mammalian cells are grown in culture at near neutral pH (such as about pH 6.5 to about pH 7.5). Typically, the temperature of the culture is controlled (e.g., the temperature is typically physiological 37° C., but can be as low as 30° C.). Typically, the oxygen concentration of the culture is 20% to 100% air saturated. In a specific embodiment, the culture is free of contaminants.
[0139] In a specific embodiment, a liquid medium with a chemically defined composition (i.e., a liquid medium in which all chemical components are known), a liquid medium without animal-derived components (i.e., a liquid medium without any component (e.g., protein or serum) derived from a mammal), a serum-free liquid medium (i.e., a liquid medium without mammalian serum), or a serum-containing liquid medium used in a fed-batch process. In some examples, one or more (e.g., one, two, or three) of a liquid medium, a first feed medium (e.g., a composite feed), and a second feed medium (e.g., a composite feed) is a liquid medium without animal components with a chemically defined composition. In some embodiments, each of the feeds comprises a liquid medium without animal components with a chemically defined composition. In some examples, each of the liquid medium, the first feed medium (e.g., a composite feed), and the second feed medium (e.g., a composite feed) is different. In some embodiments, each of the feed medium (e.g., a composite feed) is the same. In some embodiments, the feed medium (e.g., a composite feed) between different feeds is different. In some embodiments, some feed media (eg, complex feeds) are different from other feed media.
[0140] Examples of liquid culture media that can be used in the fed-batch methods described herein include, for example, CD CHO (ThermoFisher Scientific), CD-C4 (Ecplaza), CD OptiCHO™ medium (ThermoFisherScientific), CD OptiCHO TM MediumBalanCD TM CHO Feed 2, BalanCD TM CHO Feed 4 and HyClone TM ActiPro TM .
[0141] The cells can be cultured in a bioreactor containing about 100 mL to about 200 mL of culture medium, about 300 mL to about 1000 mL of culture medium, about 500 mL to about 3000 mL of culture medium, about 2000 mL to about 8000 mL of culture medium, or about 4000 mL to about 15000 mL of culture medium. In some embodiments, the cells can be cultured in a bioreactor containing about 10,000 mL to about 20,000 mL of culture medium, about 15,000 mL to about 20,000 mL of culture medium, or about 20,000 mL to 30,000 mL of culture medium.
[0142] 4.1.5 Purification of target protein
[0143] The target protein can be isolated or purified from the fed-batch culture using techniques known to those skilled in the art. For example, the target protein can be purified using hydroxyapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography. Other techniques for protein purification, such as fractionation on ion exchange columns, ethanol precipitation, reverse phase HPLC, silica gel chromatography, heparin SEPHAROSE chromatography, and the like, can be used to purify the target protein. TM Chromatography, anion or cation exchange resin (such as polyaspartic acid column) chromatography, chromatofocusing, SDS-PAGE and ammonium sulfate precipitation can also be used to purify the target protein, depending on the protein (e.g., antibody) to be recovered. After any preliminary purification steps, a mixture comprising the target protein (e.g., antibody) and contaminants can be subjected to low pH hydrophobic interaction chromatography. In some embodiments, at least or about 5% by weight (e.g., at least or about 10%, 15%, 20%, 25%, 30%, 40%, 45%, or 50% by weight) of the target protein can be separated from one or more other components (e.g., mammalian cells or culture medium proteins) present in the cell culture medium or one or more other components (e.g., DNA, RNA, or other proteins) present in the mammalian cell lysate. In some embodiments, at least or about 55%, 60%, 65%, 70%, or 75% by weight of the protein of interest can be separated from one or more other components (e.g., mammalian cells or culture media proteins) present in a cell culture medium or one or more other components (e.g., DNA, RNA, or other proteins) present in a mammalian cell lysate. In some embodiments, at least or about 80%, 85%, 90%, or 95% by weight of the protein of interest can be separated from one or more other components (e.g., mammalian cells or culture media proteins) present in a cell culture medium or one or more other components (e.g., DNA, RNA, or other proteins) present in a mammalian cell lysate.
[0144] 4.2 Metabolic model
[0145] In another aspect, the metabolic model of a mammalian cell line is used to model lactate spikes and identify factors that can reduce lactate spikes. For example, in certain embodiments, the metabolic model is an in silico model. In a specific embodiment, the computer model is a digital twin genome scale metabolic model (see, e.g., U.S. Patent Application Publication No. 2007 / 0298484, the contents of which are hereby incorporated by reference as a whole). In some embodiments, a pre-existing metabolic model of a mammalian cell line is used to model lactate spikes and identify factors that can reduce lactate spikes. In some embodiments, a metabolic model of a mammalian cell line is established from scratch and is used to model lactate spikes and identify factors that can reduce lactate spikes. In some embodiments, the model is the model described in the embodiments.
[0146] As provided herein, the metabolic model can be used and other experimental data sets (e.g., experimental data sets showing lactate spikes and experimental data sets not showing lactate spikes) are used to retrain the metabolic model. Once trained, the model can predict spikes, and is tested to identify one or more factors that can reduce lactate spikes. For example, as provided herein, the model can be used to predict metabolic factors that can reduce lactate spikes. In some embodiments, the metabolic factor is selected from the group consisting of the following items: pyruvate and amino acids. In a specific embodiment, amino acids are selected from the group consisting of the following items: asparagine (Asn), glutamic acid (Glu), isoleucine (Ile), leucine (Leu), aspartic acid (Asp), valine (Val) and threonine (Thr). In some embodiments, the model is trained as described in the examples.
[0147] In one aspect, the model provided herein can identify one or more metabolic factors that should be modified to reduce the lactate spike. For example, the model can predict that one or more metabolic factors should be increased, and / or one or more metabolic factors should be reduced. In some embodiments, the model identifies that, for example, the pyruvate concentration should be reduced, while the concentrations of glutamate, isoleucine, aspartic acid, threonine, leucine, and valine should be increased. In some embodiments, the model identifies that, for example, the pyruvate concentration should be reduced, while the concentrations of glutamate, leucine, and valine should be increased.
[0148] In another aspect, modeling prediction can be applied to bioreactors, and output (e.g., titer, rate, and / or yield) can be measured. A bioreactor can have any suitable volume that allows the cultivation and propagation of biological cells capable of producing a desired protein. For example, the volume of a bioreactor can be from about 0.5 liters (L) to about 25,000L. In some embodiments, the volume of a bioreactor can be less than or equal to about 250L. In some embodiments, the volume of a bioreactor can be from about 0.5 liters (L) to about 250L. In some embodiments, the volume of a bioreactor can be less than or equal to about 50L. In some embodiments, the volume of a bioreactor can be from about 1L to about 50L. In some embodiments, the volume of a bioreactor can be from about 1L to about 10L. In some embodiments, the volume of a bioreactor can be from about 1L to about 5L. In some embodiments, the volume of a bioreactor can be less than or equal to about 25L. In some embodiments, the volume of a bioreactor can be from about 1L to about 25L. In some embodiments, the volume of a bioreactor can be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 1L. In some embodiments, the volume of the bioreactor may be about 1L. In some embodiments, the volume of the bioreactor may be about 2L. In some embodiments, the volume of the bioreactor may be about 3L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25L. In some embodiments, the volume of the bioreactor may be less than or equal to about 50L. In some embodiments, the volume of the bioreactor may be less than or equal to about 100L. In some embodiments, the volume of the bioreactor may be less than or equal to about 250L. In some embodiments, the volume of the bioreactor may be equal to or greater than 1,000L. In some embodiments, the volume of the bioreactor may be from about 1,000L to about 25,000L. In some embodiments, the volume of the bioreactor may be from about 10,000L to about 25,000L. In some embodiments, the volume of the bioreactor may be about 1,000 L. In some embodiments, the volume of the bioreactor may be about 2,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 5,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 10,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 15,000 L. In some embodiments, the volume of the bioreactor may be less than or equal to about 25,000 L.
[0149] In some embodiments, the digital computer simulation of the fed-batch process for producing the target protein is implemented by one or more computing devices. Data characterizing the fed-batch process is received. In addition, the model of the mammalian cell line is initialized so that the fed-batch process can be simulated, thereby characterizing the lactate spike based on the received data. The simulation identifies at least one factor that contributes to the lactate spike. Data characterizing at least one factor identified is provided. The model can take various forms, including a metabolic model, which optionally includes one or more machine learning models, such as a neural network. In some embodiments, the machine learning model (e.g., a neural network, etc.) is trained using data extracted from a representative process that does not show a lactate spike and a representative process that shows a lactate spike. In some embodiments, the received data and / or the extracted data characterize one or more of the product composition, initial conditions, and nutrient addition of the fed-batch process. The provision of data can take various forms, including displaying at least one factor identified in a graphical user interface, physically storing at least one factor identified permanently, loading at least one factor identified into a memory, or transmitting at least one factor identified to a remote computing system via a network. Furthermore, in some embodiments, the at least one factor identified indicates that the pyruvate concentration of one or more feeds (e.g., one or more complex feeds) to the cells in a bioreactor in a fed-batch process needs to be reduced to reduce the lactate spike.
[0150] In some embodiments, the target protein is produced as part of a fed-batch process. Data characterizing the fed-batch process is received. In addition, a model of a mammalian cell line is initialized to enable simulation of the fed-batch process, thereby characterizing a lactate spike based on the received data. The simulation identifies at least one factor that contributes to the lactate spike. Thereafter, one or more operating parameters of the fed-batch process are modified based on the at least one factor identified. The modification may include reducing the pyruvate concentration in one or more feeds to cells in a bioreactor during the fed-batch process. In addition or as an alternative, the modification may include increasing one or more amino acids in one or more feeds to cells in a bioreactor during the fed-batch process.
[0151] 5. Examples
[0152] 5.1 Example 1: Lactate spikes observed in multiple fed-batch cultures
[0153] like Figure 1 and Figure 2As shown in , fed-batch cultures of CHO cells recombinantly expressing three different antibodies (Antibody A, Antibody B, and Antibody C) exhibited lactate spike proteins. Antibody A cultures exhibited a lactate spike between culture days 5 to 6, Antibody B cultures exhibited a lactate spike between culture days 8 to 9, and Antibody C exhibited a lactate spike between culture days 7 to 8. Figure 1 As shown in Figure 2, an increase in glucose consumption during the lactate spike was observed followed by a decrease in glucose consumption, a decrease in oxygen consumption, and an increase in the osmolarity of the culture due to base addition. However, no differences were observed in VCD, viability, or glutamine concentration. Bioreactor conditions for Antibody A included 2×10 6 vc / ml and a bioreactor (Brx) duration of 12 days. The bioreactor conditions for antibody B included 0.5×10 6 vc / ml and a 16-day Brx duration. Bioreactor conditions for Antibody C included 1.5×10 6 The inoculation density was 1.5 vc / ml and the Brx duration was 12 days. The basal medium was different for each of the three antibodies and the medium for the composite feed was different for two of the antibodies. Figure 3 As shown in , all cell lines showed a similar increase in lactate production per cell, and a decrease in glucose consumption per cell was observed for 2 to 3 cell lines after the lactate spike.
[0154] 5.2 Example 2: Using genome-based metabolic modeling to identify processes that address rapid lactate accumulation plan
[0155] When working with a fed-batch process for late-stage clinical assets, the following phenomenon occurred during the high productivity process: cells producing antibody A sporadically produced 2g / L to 3g / L lactate within 24 hours close to the peak cell density, and then the excess lactate was consumed in the rest of the fed-batch process. The culture sporadically showed a sudden lactate production between the 5th and 6th days of culture. This rapid accumulation of lactate in the fed-batch process has not appeared before and is called a "lactate spike". When this phenotype occurs, it leads to reduced glucose metabolism, reduced product expression and decreased product quality. Specifically, it was observed that during the lactate spike, glucose consumption increased, then glucose consumption decreased, oxygen consumption decreased, and the osmotic pressure molarity of the culture increased due to the addition of alkali. All tested cell lines showed that the increase in lactate production per cell was similar, and for 2 to 3 cell lines after the lactate spike, a decrease in glucose consumption per cell was observed. No differences in viable cell density (VCD), viability and glutamine concentration in the culture medium were observed.
[0156] The inventors have tried various methods to reduce or eliminate this lactate spike by adjusting the glucose feeding strategy and the rate of composite feeding learned by the spent culture medium analysis, but these methods have not been successful. The metabolic model of the pre-existing CHO cell line is used to model the lactate spike to identify the directional hypothesis that can be pursued to understand and eliminate the sudden accumulation of lactate and reduce the experimental load. Specifically, the genome-based metabolic model of the pre-existing cell line is retrained using two additional experimental data sets (experimental data sets that show lactate spikes and experimental data sets that do not show lactate spikes). Once trained, the model is able to predict spikes and is used for sensitivity analysis of the culture medium components that are most likely to contribute to lactate accumulation.
[0157] Model-based sensitivity analysis identified pyruvate and glutamic acid, leucine, threonine, asparagine, aspartic acid, isoleucine and valine as key feed components associated with the sudden accumulation of lactate. The model predicts that the concentrations of asparagine and pyruvate should be reduced, while the concentrations of aspartic acid, threonine, glutamic acid, leucine, isoleucine and valine should be increased. These results were tested in a 3L bioreactor, and reducing the pyruvate concentration in the composite feed was the biggest contributing factor to eliminate the lactate spike, accompanied by a 20% increase in titer. The results of these two co-variations, i.e., lactate reduction and titer increase, are inconsistent with each other, because the carbon flux generated by the pyruvate metabolic node is reduced and expected to reduce the flux leading to both lactate and TCA cycles. According to the hypothesis, the result of the reduction of the flux leading to the TCA cycle (tricarboxylic acid cycle) is that the titer produced by oxidative phosphorylation is reduced, but these results will show that the reduction of pyruvate can improve the redox balance of the cell, thereby reducing lactate and increasing productivity. These results were investigated using metabolic modeling using flux analysis to explain this contrary to expectations.
[0158] 5.3 Example 3: Using Digital Twins to Identify Process Solutions to Address Rapid Lactate Accumulation
[0159] This example shows that reducing the pyruvate concentration in the feed medium eliminates the lactate burst. It is proposed in this example that the lactate spike occurs due to the activation of glucose uptake by high concentrations of extracellular pyruvate. The lactate burst occurs due to the inhibitory effect of lactate on pfk, which limits glycolytic flux. This example shows that reducing the pyruvate concentration in the medium balances the rates of glycolytic flux and TCA flux.
[0160] Background and Objectives. During process optimization, a cell culture process will sporadically produce 2 g / L to 3 g / L lactate (i.e., "lactate spikes") over a 24 hour period. Lactate spikes result in reduced glucose metabolism, reduced product expression, and decreased product quality. Various methods have been attempted to reduce or eliminate lactate spikes (e.g., adjusting the rates of glucose feed and composite feed additions learned from spent culture medium analysis). These methods have been unsuccessful in mitigating lactate accumulation, and metabolic models of cell lines have been used to model lactate spikes and identify directional hypotheses that can be pursued to eliminate sudden lactate accumulations.
[0161] Antibody A cultures with lactate spike phenotype ( FIG. 4A to FIG. 4C , (solid line) and Figure 1 ) showed decreased glucose consumption, decreased oxygen uptake, and increased osmolarity (due to base addition) following a sudden lactate accumulation. Antibody B and Antibody C cultures also showed a lactate spike and changes in glucose consumption following the lactate spike ( Figure 2 and Figure 3 ). Adjustments to the complex and glucose feeding strategies and copper concentrations did not prevent the possibility of lactate spikes.
[0162] Experimental methods and results:
[0163] A computer digital twin was used to identify a directional solution. A digital twin developed specifically for cloning was retrained using two additional experimental datasets (one that exhibited lactate spikes and one that did not). Figure 5A and Figure 5B Specifically, data (e.g., features, etc.) extracted from two representative processes that exhibited either a "no lactate spike" (M19L059) or a "lactate spike" (M19L062) were used to train one or more machine learning models that formed part of a metabolic model ( Figure 6). The digital twin consists of three elements; a reactor model (describes the concentration and volume of all components added to or removed from the bioreactor), an extracellular reaction model (describes the chemical reactions occurring outside the cell), and a kinetic cell model (describes the concentration changes due to cell metabolism). The kinetic cell model consists of a metabolic network model (see, e.g., Hefzi, H. et al., "A Consensus Genome-Scale Reconstruction of Chinese Hamster Ovary Cell Metabolism", Cell Systems, 3: 434-443) and a recurrent neural network (RNN) model. Model inputs (i.e., extracted features, etc.) include product composition, initial conditions (VCD, volume, pH, etc.), and nutrient addition. The digital twin is trained by first defining the number of hyperparameters in the RNN, and then using an 80 / 20 split of the process data for training (80%) and testing (20%). The model is then cross-validated using the best hyperparameter values by redistributing the process data into training-test splits. The average of the five cross-validation metrics was used to determine the predictive quality of the model. Once the model is trained using similar inputs, a sensitivity analysis can be performed on the components of the culture medium that are most likely to contribute to lactate accumulation. Specifically, a sensitivity analysis is performed on the components of the feed culture medium that are most likely to contribute to the sudden formation of lactate using a digital twin. The analysis can be used to modify one or more operating parameters of a system / process (e.g., a fed-batch process, etc.). For example, a sensitivity analysis can identify at least one factor indicating the need to reduce the concentration of pyruvate in one or more feeds to cells in a bioreactor in a fed-batch process to reduce the lactate spike. As another example, a sensitivity analysis can identify at least one factor indicating the need to increase the concentration of one or more amino acids in one or more feeds to cells in a bioreactor in a fed-batch process to reduce the lactate spike.
[0164] Sensitivity analysis. Perform local sensitivity analysis on individual feed components. Figure 7 The heatmap in identifies components whose concentrations are associated with lactate burst formation. A summary of manipulations that reduced lactate formation is provided in Table 4. Model-based sensitivity analysis identified pyruvate, glutamate, leucine, isoleucine, asparagine, aspartate, threonine, and valine as the key media components most strongly associated with lactate burst accumulation.
[0165] Table 4
[0166]
[0167] Experimental validation of the sensitivity analysis mapped the media components with the strongest correlations to the entry points into the TCA cycle ( Figure 8 ). Experiments were designed to target multiple entry points into the TCA cycle to increase the likelihood of successfully reducing lactate spikes. Fig.12 .
[0168] Experimental validation of results. Results were tested in a 3L bioreactor and reducing the pyruvate concentration in the composite feed was the biggest contributor to eliminating the lactate spike. Reducing the pyruvate concentration of the feed medium consistently reduced lactate and increased titer (approximately 20%). The reduced pyruvate concentration increased flux to the TCA cycle, resulting in a 20% increase in titer. See FIG. 9A to FIG. 9B and FIG. 10A to FIG. 10B And Table 5.
[0169] Table 5
[0170] At 120 hours of flux Flux ratio between lactate spike process / low pyruvate process Pyruvate uptake 32 Glucose uptake 1.5 Lactate secretion 4
[0171] discuss:
[0172] The key difference between the control and low pyruvate medium processes was that the glucose uptake rate was significantly higher (1.5×) in the control process. Unexpectedly, the TCA cycle flux was similar in both processes. Therefore, reducing the pyruvate concentration in the culture medium reduced lactate production primarily by reducing the glucose uptake rate.
[0173] Although the control process took up more pyruvate, the flux from glucose to lactate was higher in the control (60%) than in the low pyruvate medium process (25%). Therefore, the lactate spike in the control process was caused by the higher glucose uptake.
[0174] High glucose uptake and glycolytic flux depletes cytoplasmic NAD + Faster than the Asp-Mal cycle replenishes cytoplasmic NAD+. Cells use the LDH response to generate NAD that causes the lactate spike + .
[0175] Finally, the mechanism by which high concentrations of pyruvate in the medium cause cells to consume more glucose is unknown. However, without being bound by theory, it is hypothesized that the effect is of a regulatory nature. The dramatic decrease in lactate is probably due to the inhibitory effect of lactate on the enzyme pfk, which reduces flux through glycolysis. This increases the NAD+ / NADH ratio and allows cells to consume lactate as a substrate. See Fig.11 .
[0176] Reducing the pyruvate concentration in the feed medium abolished the lactate spike. It has been proposed that the lactate spike occurs due to the activation of glucose uptake by high concentrations of extracellular pyruvate. The lactate spike occurs due to the inhibitory effect of lactate on pfk, which limits glycolytic flux. Reducing the pyruvate concentration in the medium balances the rates of glycolytic flux and TCA flux. Studies are planned to monitor the intracellular and extracellular redox environment to confirm the role in the lactate spike.
[0177] References for Example 2
[0178] 1. Wilkens CA,Gerdtzen ZP.PLoS ONE.2015;10(3):1-15
[0179] 2.Hartley, F., et al., Biotech and Bioeng. 2018;115:1890-1903.
[0180] 3. Mulukutla, BC, et al., Trends in Biotechnol. 2016; 34(8): 638-651.
[0181] 4. J., et al., Eng Life Sci. 2021:100-114.
[0182] 6. Implementation Plan
[0183] The present invention provides the following non-limiting embodiments.
[0184] 1. A method for reducing a lactate spike in a fed-batch process for producing a protein of interest, wherein the method comprises reducing the pyruvate concentration in one or more feeds to cells comprising a nucleic acid encoding the protein in a bioreactor in the fed-batch process.
[0185] 2. A method for increasing the titer of a target protein produced by cells in a fed-batch culture process, the method comprising reducing the concentration of pyruvate in one or more feeds to the cells in a bioreactor in the fed-batch process.
[0186] 3. The method according to embodiment 1 also includes increasing the concentration of one or more amino acids in the one or more feeds.
[0187] 4. The method according to embodiment 2, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine or a combination thereof.
[0188] 5. The method according to embodiment 2, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine and leucine or a combination thereof.
[0189] 6. The method of embodiment 2, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
[0190] 7. The method of any one of embodiments 3 to 6, wherein the amino acid concentration is increased by about 0% to about 100%.
[0191] 8. The method of any one of embodiments 1 to 7, wherein the pyruvate concentration is reduced by about 65% to about 100%.
[0192] 9. The method of any one of embodiments 1 to 8, wherein the cell is a CHO cell.
[0193] 10. The method according to any one of embodiments 1 to 9, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme or a coagulant.
[0194] 11. A method according to embodiment 10, wherein the antibody binds to a glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
[0195] 12. The method of embodiment 10, wherein the antibody binds to an antigen of a pathogen.
[0196] 13. The method of embodiment 12, wherein the pathogen is a virus, a bacterium, a fungus or a parasite.
[0197] 14. The method of embodiment 10, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0198] 15. A method for producing a target protein, the method comprising:
[0199] (a) culturing the cells comprising a nucleic acid encoding the protein in a fed-batch manner in a bioreactor under conditions sufficient for the cells to produce the protein, wherein the fed-batch culturing comprises adding a volume of one or more feeds having a pyruvate concentration that is 65% to 100% lower than the pyruvate concentration used in a fed-batch culturing of the cells under the same conditions under which a lactate spike is observed; and
[0200] (b) purifying the protein from the cells or liquid culture medium.
[0201] 16. A method according to embodiment 15, wherein the concentration of one or more amino acids in the one or more feeds is increased by about 0% to about 100% relative to the fed-batch culture of the cells carried out under the same conditions where the lactate spike is observed.
[0202] 17. The method according to embodiment 16, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine or a combination thereof.
[0203] 18. The method according to embodiment 16, wherein the one or more amino acids are selected from the group consisting of: glutamic acid, valine and leucine or a combination thereof.
[0204] 19. The method of embodiment 16, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
[0205] 20. The method of any one of embodiments 15 to 19, wherein the cell is a CHO cell.
[0206] 21. The method of any one of embodiments 15 to 20, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme, or a coagulant.
[0207] 22. A method according to embodiment 21, wherein the antibody binds to a glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
[0208] 23. The method of embodiment 21, wherein the antibody binds to an antigen of a pathogen.
[0209] 24. The method of embodiment 23, wherein the pathogen is a virus, a bacterium, a fungus or a parasite.
[0210] 25. A method according to embodiment 21, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0211] 26. A method for providing a digital computer simulation of a fed-batch process for producing a target protein, the method being implemented by one or more computing devices, and comprising:
[0212] receiving data characterizing the fed-batch process;
[0213] Initialize the model in mammalian cell lines;
[0214] simulating the fed-batch process using the initialized model and the received data to characterize a lactate spike;
[0215] Based on the modeling, identifying at least one factor that contributes to the lactate spike; and
[0216] Data characterizing the identified at least one factor is provided.
[0217] 27. The method of embodiment 26, wherein the data provided characterizes one or more of product composition, initial conditions, and nutrient addition of the fed-batch process.
[0218] 28. A method according to embodiment 26 or 27, wherein the model is a metabolic model.
[0219] 29. A method according to any one of embodiments 26 to 28, wherein the model includes one or more machine learning models.
[0220] 30. A method according to embodiment 29, wherein the one or more machine learning models include: a neural network.
[0221] 31. The method according to embodiment 30, further comprising:
[0222] The neural network was trained using data extracted from representative processes that did not exhibit lactate spikes and representative processes that exhibited lactate spikes.
[0223] 32. The method of embodiment 31, wherein the extracted data characterizes one or more of product composition, initial conditions, and nutrient addition of the fed-batch process.
[0224] 33. The method of any one of embodiments 26 to 32, wherein providing data comprises one or more of:
[0225] The identified at least one factor is displayed in a graphical user interface, physically and permanently stored, loaded into a memory, or transmitted to a remote computing system over a network.
[0226] 34. The method of any one of embodiments 26 to 33, wherein the at least one factor identified indicates that the pyruvate concentration in one or more feeds to cells in the bioreactor in the fed-batch process needs to be reduced to reduce the lactate spike.
[0227] 35. The method of any one of embodiments 26 to 34, wherein the at least one factor identified indicates that the concentration of one or more amino acids in one or more feeds to cells in the bioreactor in the fed-batch process needs to be increased to reduce the lactate spike.
[0228] 36. A method for producing a target protein as part of a fed-batch process, the method comprising:
[0229] receiving data characterizing the fed-batch process;
[0230] Initialize the model in mammalian cell lines;
[0231] simulating the fed-batch process using the initialized model and the received data to characterize a lactate spike;
[0232] Based on the modeling, identifying at least one factor that contributes to the lactate spike; and
[0233] One or more operating parameters of the fed-batch process are modified based on the identified at least one factor.
[0234] 37. A method according to embodiment 36, wherein the modification comprises reducing the pyruvate concentration in one or more feeds to cells in the bioreactor in the fed-batch process.
[0235] 38. The method of embodiment 36 or 37, wherein the modification comprises increasing one or more amino acids in one or more feeds to cells in a bioreactor in the fed-batch process.
[0236] 39. A method for reducing a lactate spike during a fed-batch culture of cells, the method comprising feeding a batch culture of cells comprising a nucleic acid encoding a target protein in a bioreactor under conditions sufficient for the cells to produce the protein, wherein the fed-batch culture comprises adding a volume of a first composite feed within 0 to 3 days after initiation of the fed-batch culture of the cells, wherein the first composite feed has a first pyruvate concentration, and wherein the first pyruvate concentration is about 65% to about 100% lower than the pyruvate concentration used in the fed-batch culture of the cells conducted under the same conditions where a lactate spike is observed.
[0237] 40. The method of embodiment 39, wherein the concentration of one or more amino acids is increased.
[0238] 41. The method of embodiment 40, wherein the increase in concentration of the one or more amino acids is from about 0% to about 100%.
[0239] 42. The method of embodiment 40 or 41, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine, or a combination thereof.
[0240] 43. The method of embodiment 40 or 41, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine and leucine or a combination thereof.
[0241] 44. The method of embodiment 40 or 41, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
[0242] 45. The method of any one of embodiments 39 to 44, wherein the cell is a CHO cell.
[0243] 46. The method of any one of embodiments 39 to 45, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme, or a coagulant.
[0244] 47. A method according to embodiment 46, wherein the antibody binds to a glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
[0245] 48. The method of embodiment 46, wherein the antibody binds to an antigen of a pathogen.
[0246] 49. The method of embodiment 48, wherein the pathogen is a virus, bacteria, fungus or parasite.
[0247] 50. A method according to embodiment 46, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0248] 51. A method for identifying the pyruvate concentration used in one or more composite feeds in a fed-batch process, the method comprising:
[0249] (a) culturing cells comprising a nucleic acid encoding a protein of interest in a first bioreactor under conditions sufficient for the cells to produce the protein, wherein the fed-batch culturing comprises adding a volume of one or more complex feeds, wherein the one or more complex feeds have a first pyruvate concentration;
[0250] (b) culturing the same cells in a second bioreactor under the same conditions as used for the fed-batch culturing in step (a), except that the one or more complex feeds have a second pyruvate concentration, wherein the second pyruvate concentration is about 65% to 100% lower than the first pyruvate concentration;
[0251] (c) measuring the lactate concentration in the fed-batch culture in step (a) within about 12 hours to about 72 hours after each batch of complex feeding, and measuring the lactate concentration in the fed-batch culture in step (b) within about 12 hours to about 72 hours after each batch of complex feeding; and
[0252] (d) comparing the measured lactate concentration of the fed-batch culture in step (a) with the measured lactate concentration of the fed-batch culture in step (b), wherein a decrease in the lactate concentration of the fed-batch culture in step (b) relative to the lactate concentration of the fed-batch culture in step (a) indicates that the pyruvate concentration used for the one or more composite feeds in the fed-batch culture in step (b) is better for fed-batch culture of the cells in a bioreactor; and
[0253] (e) producing the protein by fed-batch culturing the cells under conditions sufficient for the cells comprising the nucleic acid to produce the recombinant protein, wherein the fed-batch culturing comprises adding a volume of one or more complex feeds, wherein the one or more complex feeds have the second pyruvate concentration.
[0254] 52. A method according to embodiment 51, wherein the cells are CHO cells.
[0255] 53. The method of embodiment 51 or 52, wherein the target protein is an antibody, cytokine, antigen, enzyme or coagulant.
[0256] 54. A method according to embodiment 53, wherein the antibody binds to a glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
[0257] 55. The method of embodiment 53, wherein the antibody binds to an antigen of a pathogen.
[0258] 56. The method of embodiment 55, wherein the pathogen is a virus, bacteria, fungus or parasite.
[0259] 57. A method according to embodiment 53, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
[0260] 58. A method for reducing lactate spikes during a fed-batch culture of cells, the method comprising culturing the cells in a bioreactor under conditions sufficient for cells comprising a nucleic acid encoding a target protein to produce the protein, wherein the fed-batch culture comprises adding one or more feeds during expansion of the cells and reducing the concentration of pyruvate in one or more additional composite feeds prior to peak cell density, wherein during expansion of the cells, the concentration of pyruvate in the one or more additional composite feeds is reduced by 65% to 100% relative to the concentration of pyruvate in the one or more composite feeds.
[0261] 59. A method according to embodiment 58, wherein in the fed-batch culture of the cells, the peak cell density is about 6 days to about 7 days, and in the fed-batch culture of the cells, the decrease in the pyruvate concentration in the one or more additional composite feeds is about day 3 to day 5.
[0262] 60. The method of embodiment 58 or 59, wherein the concentration of one or more amino acids in one or more additional feeds is increased prior to peak cell density.
[0263] 61. A method according to embodiment 60, wherein during the expansion of the cells, the concentration of the one or more amino acids in the one or more additional complex feeds is increased by 0% to 100% relative to the concentration of the one or more amino acids in the one or more complexes.
[0264] 62. The method of embodiment 60 or 61, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine, or a combination thereof.
[0265] 63. The method of embodiment 60 or 61, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine and leucine or a combination thereof.
[0266] 64. The method of embodiment 60 or 61, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
[0267] 65. The method of any one of embodiments 58 to 64, wherein the cell is a CHO cell.
[0268] In the above description and claims, phrases such as "at least one of" or "one or more of" may appear after a connected list of elements or features. The term "and / or" may also appear in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it is used, such a phrase is intended to mean any of the listed elements or features alone or in combination with any of the other listed elements or features. For example, the phrases "at least one of A and B"; "one or more of A and B"; and "A and / or B" are each intended to mean "A alone, B alone, or A and B together." A similar interpretation applies to lists including three or more items. For example, the phrases "at least one of A, B, and C"; "one or more of A, B, and C"; and "A, B, and / or C" are each intended to mean "A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together." The term "based on" used above and in the claims is intended to mean "based at least in part on," such that unlisted features or elements are also allowed.
[0269] The subject matter described herein, including the initialized models and the execution of any such models generated, can be implemented using a variety of computing devices, including computing systems, including back-end components (e.g., as a data server), or including middleware components (e.g., an application server), or including front-end components (e.g., a client computer with a graphical user interface or a web browser through which a user can interact with a specific implementation of the subject matter described herein), or any combination of such back-end, middleware, or front-end components. The components of the system can be interconnected by any form or medium of digital data communication (e.g., a communication network). Examples of communication networks include a local area network ("LAN"), a wide area network ("WAN"), and the Internet. These various embodiments can include specific implementations in one or more computer programs that can be executed and / or interpreted on a programmable system including at least one programmable processor, which can be special purpose or general purpose, coupled to receive data and instructions from and transmit data and instructions to a storage system, at least one input device, and at least one output device.
[0270] Depending on the desired configuration, the subject matter described herein may be embodied in systems, devices, methods and / or articles. The specific implementations set forth in the foregoing description do not represent all specific implementations consistent with the subject matter described herein. On the contrary, they are merely some examples consistent with various aspects related to the described subject matter. Although some variations have been described in detail above, other modifications or additions are also possible. Specifically, in addition to those set forth herein, additional feature parts and / or variations may also be provided. For example, the specific implementations described above may involve various combinations and sub-combinations of the disclosed feature parts and / or combinations and sub-combinations of several additional feature parts disclosed above. In addition, the logic flow described herein does not necessarily require the specific order or sequential order shown to achieve the desired results. Other specific implementations may be within the scope of the following claims.
Claims
1. A method for reducing a lactate spike in a fed-batch process for producing a protein of interest, wherein the method comprises reducing the pyruvate concentration in one or more feeds to cells comprising a nucleic acid encoding the protein in a bioreactor in the fed-batch process.
2. A method for increasing the titer of a target protein produced by cells in a fed-batch culture process, the method comprising reducing the concentration of pyruvate in one or more feeds to the cells in a bioreactor in the fed-batch process.
3. The method of claim 1, further comprising increasing the concentration of one or more amino acids in the one or more feeds.
4. The method according to claim 2, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine or a combination thereof.
5. The method of claim 2, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine and leucine, or a combination thereof.
6. The method of claim 2, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
7. The method of any one of claims 3 to 6, wherein the amino acid concentration is increased by about 0% to about 100%.
8. The method of any one of claims 1 to 7, wherein the pyruvate concentration is reduced by about 65% to about 100%.
9. The method according to any one of claims 1 to 8, wherein the cells are CHO cells.
10. The method according to any one of claims 1 to 9, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme or a coagulant.
11. The method of claim 10, wherein the antibody binds to glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B-cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
12. The method of claim 10, wherein the antibody binds to an antigen of a pathogen.
13. The method of claim 12, wherein the pathogen is a virus, a bacterium, a fungus or a parasite.
14. The method of claim 10, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9 or IL-17.
15. A method for producing a target protein, the method comprising: (a) culturing the cells comprising a nucleic acid encoding the protein in a fed-batch culture in a bioreactor under conditions sufficient for the cells to produce the protein, wherein the fed-batch culture comprises adding a volume of one or more complex feeds having a pyruvate concentration that is 65% to 100% lower than the pyruvate concentration used in a fed-batch culture of the cells under the same conditions under which a lactate spike is observed; as well as (b) purifying the protein from the cells or liquid culture medium.
16. The method of claim 15, wherein the concentration of one or more amino acids in the one or more feeds is increased by about 0% to about 100% relative to the fed-batch culture of the cells conducted under the same conditions where a lactate spike is observed.
17. The method of claim 16, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine, or a combination thereof.
18. The method of claim 16, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, and leucine, or a combination thereof.
19. The method of claim 16, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
20. The method according to any one of claims 15 to 19, wherein the cells are CHO cells.
21. The method according to any one of claims 15 to 20, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme or a coagulant.
22. The method of claim 21, wherein the antibody binds to glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha-fetoprotein (AFP), B-cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
23. The method of claim 21, wherein the antibody binds to an antigen of a pathogen.
24. The method of claim 23, wherein the pathogen is a virus, bacteria, fungus or parasite.
25. The method of claim 21, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9, or IL-17.
26. A method for providing a digital computer simulation of a fed-batch process for producing a target protein, the method being implemented by one or more computing devices, and comprising: receiving data characterizing the fed-batch process; Initialize the model in mammalian cell lines; simulating the fed-batch process using the initialized model and the received data to characterize a lactate spike; Based on the modeling, identifying at least one factor that contributes to the lactate spike; as well as Data characterizing the identified at least one factor is provided.
27. The method of claim 26, wherein the data provided characterizes one or more of product composition, initial conditions, and nutrient additions of the fed-batch process.
28. The method of claim 26 or 27, wherein the model is a metabolic model.
29. A method according to any one of claims 26 to 28, wherein the model comprises one or more machine learning models.
30. The method of claim 29, wherein the one or more machine learning models include: Neural network.
31. The method of claim 30, further comprising: The neural network was trained using data extracted from representative processes that did not exhibit lactate spikes and representative processes that exhibited lactate spikes.
32. The method of claim 31 , wherein the extracted data characterizes one or more of product composition, initial conditions, and nutrient additions of the fed-batch process.
33. The method of any one of claims 26 to 32, wherein providing data comprises one or more of: The identified at least one factor is displayed in a graphical user interface, physically and permanently stored, loaded into a memory, or transmitted to a remote computing system over a network.
34. The method of any one of claims 26 to 33, wherein the at least one factor identified indicates that the pyruvate concentration in one or more feeds to cells in a bioreactor in the fed-batch process needs to be reduced in order to reduce the lactate spike.
35. The method of any one of claims 26 to 34, wherein the at least one factor identified indicates that the concentration of one or more amino acids in one or more feeds to cells in a bioreactor in the fed-batch process needs to be increased to reduce the lactate spike.
36. A method for producing a target protein as part of a fed-batch process, the method comprising: receiving data characterizing the fed-batch process; Initialize the model in mammalian cell lines; simulating the fed-batch process using the initialized model and the received data to characterize a lactate spike; Based on the modeling, identifying at least one factor that contributes to the lactate spike; as well as One or more operating parameters of the fed-batch process are modified based on the identified at least one factor.
37. The method of claim 36, wherein the modifying comprises reducing the pyruvate concentration in one or more feeds to cells in a bioreactor in the fed-batch process.
38. The method of claim 36 or 37, wherein the modifying comprises: One or more amino acids are increased in one or more feeds to cells in a bioreactor in the fed-batch process.
39. A method for reducing a lactate spike during a fed-batch culture of cells, the method comprising feeding a batch culture of cells comprising a nucleic acid encoding a target protein in a bioreactor under conditions sufficient for the cells to produce the protein, wherein the fed-batch culture comprises adding a volume of a first composite feed within 0 to 3 days after initiation of the fed-batch culture of the cells, wherein the first composite feed has a first pyruvate concentration, and wherein the first pyruvate concentration is about 65% to about 100% lower than the pyruvate concentration used in the fed-batch culture of the cells conducted under the same conditions where a lactate spike is observed.
40. The method of claim 39, wherein the concentration of one or more amino acids is increased.
41. The method of claim 40, wherein the increase in the concentration of the one or more amino acids is from about 0% to about 100%.
42. The method of claim 40 or 41, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine, or a combination thereof.
43. The method of claim 40 or 41, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine and leucine, or a combination thereof.
44. The method of claim 40 or 41, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
45. The method of any one of claims 39 to 44, wherein the cell is a CHO cell.
46. The method of any one of claims 39 to 45, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme or a coagulant.
47. The method of claim 46, wherein the antibody binds to a glioma-associated antigen, carcinoembryonic antigen (CEA), beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), B-cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor or mesothelin.
48. The method of claim 46, wherein the antibody binds to an antigen of a pathogen.
49. The method of claim 48, wherein the pathogen is a virus, bacteria, fungus or parasite.
50. The method of claim 46, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9, or IL-17.
51. A method for identifying the pyruvate concentration used in one or more composite feeds in a fed-batch process, the method comprising: (a) culturing cells comprising a nucleic acid encoding a protein of interest in a first bioreactor under conditions sufficient for the cells to produce the protein, wherein the fed-batch culturing comprises adding a volume of one or more complex feeds, wherein the one or more complex feeds have a first pyruvate concentration; (b) culturing the same cells in a second bioreactor under the same conditions as used for the fed-batch culturing in step (a), except that the one or more complex feeds have a second pyruvate concentration, wherein the second pyruvate concentration is about 65% to 100% lower than the first pyruvate concentration; (c) measuring the lactate concentration in the fed-batch culture in step (a) within about 12 hours to about 72 hours after each batch of complex feeding, and measuring the lactate concentration in the fed-batch culture in step (b) within about 12 hours to about 72 hours after each batch of complex feeding; and (d) comparing the measured lactate concentration of the fed-batch culture in step (a) with the measured lactate concentration of the fed-batch culture in step (b), wherein a decrease in the lactate concentration of the fed-batch culture in step (b) relative to the lactate concentration of the fed-batch culture in step (a) indicates that the pyruvate concentration used for the one or more composite feeds in the fed-batch culture in step (b) is better for fed-batch culture of the cells in a bioreactor; and (e) producing the protein by fed-batch culturing the cells under conditions sufficient for the cells comprising the nucleic acid to produce the recombinant protein, wherein the fed-batch culturing comprises adding a volume of one or more complex feeds, wherein the one or more complex feeds have the second pyruvate concentration.
52. The method of claim 51, wherein the cells are CHO cells.
53. The method of claim 51 or 52, wherein the target protein is an antibody, a cytokine, an antigen, an enzyme or a coagulant.
54. The method of claim 53, wherein the antibody binds to a glioma-associated antigen, carcinoembryonic antigen (CEA), beta-human chorionic gonadotropin, alpha-fetoprotein (AFP), B-cell maturation antigen (BCMA), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, GPRC5D, RU1, RU2(AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostate enzyme, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostaglandin, PSMA, HER2 / neu, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), CD70, CD20, MAGE, ELF2M, neutrophil elastase, ephrinB2, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor, or mesothelin.
55. The method of claim 53, wherein the antibody binds to an antigen of a pathogen.
56. The method of claim 55, wherein the pathogen is a virus, bacteria, fungus or parasite.
57. The method of claim 53, wherein the cytokine is IL-12, IL-23, IL-1β, IL-6, IL-15, IL-2, IL-5, TNF-α, IL-9, or IL-17.
58. A method for reducing lactate spikes during a fed-batch culture of cells, the method comprising culturing the cells in a bioreactor under conditions sufficient for cells comprising a nucleic acid encoding a target protein to produce the protein, wherein the fed-batch culture comprises adding one or more complex feeds during expansion of the cells, and reducing the concentration of pyruvate in the one or more additional complex feeds prior to peak cell density, wherein during expansion of the cells, the concentration of pyruvate in the one or more additional complex feeds is reduced by 65% to 100% relative to the concentration of pyruvate in the one or more complex feeds.
59. The method of claim 58, wherein in the fed-batch culture of the cells, the peak cell density is at about day 6 to about day 7, and in the fed-batch culture of the cells, the decrease in pyruvate concentration in one or more additional feeds is at about day 3 to day 5.
60. The method of claim 58 or 59, wherein the concentration of one or more amino acids in one or more additional feeds is increased prior to peak cell density.
61. The method of claim 60, wherein during expansion of the cells, the concentration of the one or more amino acids in the one or more additional complex feeds is increased by 0% to 100% relative to the concentration of the one or more amino acids in the one or more complexes.
62. The method of claim 60 or 61, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine, leucine, threonine, aspartic acid and isoleucine, or a combination thereof.
63. The method of claim 60 or 61, wherein the one or more amino acids are selected from the group consisting of glutamic acid, valine and leucine, or a combination thereof.
64. The method of claim 60 or 61, wherein the one or more amino acids are glutamic acid, valine, or a combination thereof.
65. The method of any one of claims 58 to 64, wherein the cell is a CHO cell.
Citation Information
Patent Citations
Method and Device for Thermal Conditioning of a Cell
US20070298484A1
Recombinant immunoglobin preparations
US4816567A
Humanized antibodies and methods for making them
US6054297A
Human antibodies derived from immunized xenomice
US6075181A
Human antibodies derived from immunized xenomice
US6150584A
